<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00975130</url>
  </required_header>
  <id_info>
    <org_study_id>P06129</org_study_id>
    <secondary_id>2009-011137-26</secondary_id>
    <secondary_id>CTRI/2009/091/000883</secondary_id>
    <nct_id>NCT00975130</nct_id>
  </id_info>
  <brief_title>Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)</brief_title>
  <acronym>GO-MORE</acronym>
  <official_title>An Open-Label Study Assessing the Addition of Subcutaneous Golimumab (GLM) to Conventional Disease-Modifying Antirheumatic Drug (DMARD) Therapy in Biologic-Na√Øve Subjects With Rheumatoid Arthritis (Part 1), Followed by a Randomized Study Assessing the Value of Combined Intravenous and Subcutaneous GLM Administration Aimed at Inducing and Maintaining Remission (Part 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1 of this trial will assess the safety and effectiveness of subcutaneous (SC) golimumab
      administered by autoinjector once monthly, when combined with different disease-modifying
      antirheumatic drug (DMARD) regimens used in daily rheumatology practice. Subsequently, Part 2
      will study if a strategy of intravenous (IV) golimumab to induce remission followed by SC
      golimumab to retain remission is superior to continuing a SC regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants who had a good or moderate European League Against Rheumatism (EULAR) response
      but not achieve remission at the end of Part 1 were invited to participate in Part 2 and were
      randomized to either intravenous golimumab (IV GLM) + subcutaneous golimumab (SC GLM) or SC
      GLM alone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>EULAR response was assessed at the end of Month 6 by the Disease Activity Score using the 28 tender and swollen joint count calculated with erythrocyte sedimentation rate values (DAS28-ESR). A good response was defined as a decrease &gt;1.2 units and a final DAS28-ESR &lt; 3.2 units, while a moderate response was defined as a decrease &gt; 1.2 units and final DAS28-ESR &gt;= 3.2 units, OR a decrease of 0.6 to 1.2 units AND final DAS28-ESR &lt;= 5.1 units</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at the Start of Month 11 and End of Month 12</measure>
    <time_frame>Start of Month 11, End of Month 12</time_frame>
    <description>The number of participants experiencing DAS28-ESR remission was evaluated at the start of study Month 11 and the end of study Month 12. The DAS28-ESR is expressed on a unit on a scale with the minimum score=0 (best) to maximum score=10 (worst). Remission was defined as DAS28-ESR &lt;2.6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Swollen Joints by Concomitant Methotrexate (MTX) Dose at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the mean number of swollen joints was calculated at study Month 2, Month 4, and Month 6 by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week). A total of 28 joints were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of swollen joints was calculated by participant baseline background DMARD treatment regimen at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Swollen Joints by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of swollen joints by participant baseline concomitant corticosteroid treatment was calculated at study Month 2, Month 4, and Month 6 . A total of 28 joints were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Swollen Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the mean number of swollen joints by the number of baseline participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Swollen Joints by Duration of Disease at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the mean number of swollen joints was calculated by the participant duration of disease at study Month 2, Month 4, and Month 6. The participant duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. A total of 28 joints were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Swollen Joints by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of swollen joints by participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6 by the participant's level of baseline disease activity, as measured by DAS28-ESR. A total of 28 joints were evaluated. DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Swollen Joints by Baseline Rheumatoid Factor (RF) Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The change from baseline in the mean number of swollen joints was calculated by the participant baseline level of RF at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Swollen Joints by Baseline Anti-Cyclic Citrullinated Antibody (Anti-CCP) Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The change from baseline in the mean number of swollen joints was calculated by the participant baseline level of anti-CCP at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The change from baseline in the mean number of swollen joints was calculated by the baseline participant smoking status at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Swollen Joints by Eligibility for Anti-Tumor Necrosis Factor (Anti-TNF) Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The change from baseline in the mean number of swollen joints was calculated by the baseline participant eligibility for anti-TNF treatment at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Swollen Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of swollen joints was calculated by the participant baseline expectation of treatment outcome at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of swollen joints was calculated by the physician experience level at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of swollen joints was calculated by the physician experience level with biologics at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Swollen Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of swollen joints was calculated by the baseline number of patients the physician treats with biologics at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. The number of patients treated with biologics is defined as the number of patients treated by the physician in the last month with biologics for rheumatoid arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Swollen Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of swollen joints was calculated by the physician's expectation of treatment outcome at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. The physician's expectation of treatment outcomes was assessed at the start of Month 4 at which time physicians were asked to rate their expectations of treatment outcome in each participant as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Tender Joints by Concomitant MTX Dose at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of tender joints was calculated by participant concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of tender joints was calculated by participant background DMARD treatment at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Tender Joints by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of tender joints was calculated by participant baseline concomitant steroid treatment at study Month 2, Month 4, and Month 6. A total 28 joints were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Tender Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of tender joints was calculated by the number of participant DMARD failures at baseline at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Tender Joints by Duration of Disease at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of tender joints was calculated by the participant duration of disease at study Month 2, Month 4, and Month 6. Duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. A total of 28 joints were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Tender Joints by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of tender joints was calculated by the participant baseline level of disease activity, as measured by DAS28, at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Tender Joints by Baseline RF Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The change from baseline in the mean number of tender joints was calculated by the participant baseline level of RF at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Tender Joints by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of tender joints was calculated by the participant baseline level of anti-CCP at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of tender joints was calculated by the baseline participant smoking status at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Tender Joints by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of tender joints was calculated by the baseline participant eligibility for anti-TNF treatment at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Tender Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of tender joints was calculated by the participant baseline expectation of treatment outcome at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of tender joints was calculated by the physician experience level at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of tender joints was calculated by the physician experience level with biologics at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Tender Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of tender joints was calculated by the baseline number of patients the physician treats with biologics at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. The number of patients treated with biologics is defined as the number of patients treated by the physician in the last month with biologics for rheumatoid arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Tender Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the number of tender joints. was calculated by the physician's expectation of treatment outcome at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. The physician's expectation of treatment outcomes was assessed at the start of Month 4 at which time physicians were asked to rate their expectations of treatment outcome in each participant as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant global assessment of disease activity was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a visual analogue scale (VAS; 0mm [best] -100mm [worst]) with increasing scores indicating increased level of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the participant global assessment of disease activity by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Participant Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the participant global assessment of disease activity score by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the participant global assessment of disease activity by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the participant global assessment of disease activity by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the participant global assessment of disease activity by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the participant global assessment of disease activity by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the participant global assessment of disease activity by participant baseline smoking status was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the participant global assessment of disease activity by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the participant global assessment of disease activity by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the participant global assessment of disease activity by the treating physician level of experience was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mm [Best]Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the participant global assessment of disease activity by physician experience level with biologics was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Participant Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the participant global assessment of disease activity by the number of patients treated with biologics by the treating physician was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Participant Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the participant global assessment of disease activity by the physician's expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Erythrocyte Sedimentation Rate (ESR) by Concomitant MTX Dose at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The change from baseline in participant serum ESR was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum ESR by concomitant DMARD background treatment was calculated at study Month 2, Month 4, and Month 6. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in ESR by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in serum ESR by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in ESR by the Number of DMARD Failures at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum ESR by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in ESR by Duration of Disease at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the participant serum ESR by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in ESR by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum ESR by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in ESR by Baseline RF Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum ESR by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in ESR by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in ESR by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum ESR by participant baseline smoking status was calculated at study Month 2, Month 4, and Month 6. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in ESR by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum ESR by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in ESR by Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum ESR by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in ESR by Physician Experience Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum ESR by the treating physician level of experience was evaluated at study Month 2, Month 4, and Month 6. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in ESR by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum ESR by physician experience level with biologics was evaluated at study Month 2, Month 4, and Month 6. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in ESR by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum ESR by the number of patients treated with biologics by the treating physician was evaluated at study Month 2, Month 4, and Month 6. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum ESR by the physician's expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in C-Reactive Protein (CRP) by Concomitant MTX Dose at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The change from baseline in participant serum CRP was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum CRP by concomitant DMARD background treatment was calculated at study Month 2, Month 4, and Month 6. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CRP by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in serum CRP by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CRP by the Number of DMARD Failures at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum CRP by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CRP by Duration of Disease at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the participant serum CRP by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CRP by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum CRP by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. DAS28-ESR scores of &gt; 3.2 to &lt;=5.1 indicate moderate disease activity and DAS28-ESR scores of &gt; 5.1 indicate high disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CRP by Baseline RF Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum CRP by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CRP by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in CRP by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum CRP by participant baseline smoking status was calculated at study Month 2, Month 4, and Month 6. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CRP by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum CRP by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CRP by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum CRP by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CRP by Physician Experience Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum CRP by the treating physician level of experience was evaluated at study Month 2, Month 4, and Month 6. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CRP by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum CRP by physician experience level with biologics was evaluated at study Month 2, Month 4, and Month 6. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CRP by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum CRP by the number of patients treated with biologics by the treating physician was evaluated at study Month 2, Month 4, and Month 6. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in participant serum CRP by the physician's expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in physician global assessment of disease activity was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the physician global assessment of disease by concomitant DMARD background treatment was evaluated at Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the physician global assessment of disease activity by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Physician Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the physician global assessment of disease activity score by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the physician global assessment of disease activity by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the physician global assessment of disease activity by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the physician global assessment of disease activity by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the physician global assessment of disease activity by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the physician global assessment of disease activity by participant baseline smoking status was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the physician global assessment of disease activity by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the physician global assessment of disease activity by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] -100mm [worst]) with increasing scores indicating increased level of disease. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the physician global assessment of disease activity by the treating physician level of experience was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the physician global assessment of disease activity by physician experience level with biologics was evaluated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the physician global assessment of disease activity by the number of patients treated with biologics by the treating physician was evaluated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the physician global assessment of disease activity by the baseline physician expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-ESR Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the DAS28-ESR was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The DAS28-ESR measures disease burden using patient global health (self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX+sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-ESR by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the DAS28-ESR by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt;3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-ESR Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the DAS28-ESR score by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed on a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-ESR Score by Duration of Disease at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the DAS28-ESR score by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed on a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt;5.1 = high disease activity, DAS28-ESR &lt;3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-ESR Score by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the DAS28-ESR score by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR with increasing scores indicating increased level of disease burden. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-ESR Score by Baseline RF Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the DAS28-ESR by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. Increasing scores indicate increased burden of disease. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-ESR Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the DAS28-ESR score by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. Increasing scores indicate increased burden of disease. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-ESR Score by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the DAS28-ESR score by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-ESR Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the DAS28-ESR score by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-ESR Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-CRP Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the DAS28-CRP was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts &amp; swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP &gt;5.1 =high disease activity, DAS28-CRP &lt;3.2=low disease activity, and DAS28-CRP &lt;2.6=remission. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 =leflunomide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-CRP by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the DAS28-CRP by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-CRP Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the DAS28-CRP score by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-CRP Score by Duration of Disease at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the DAS28-CRP score by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-CRP Score by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the DAS28-CRP score by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP with increasing scores indicating increased burden of disease. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-CRP &gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-CRP Score by Baseline RF Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the DAS28-CRP by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-CRP Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the DAS28-CRP score by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-CRP Score by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the DAS28-CRP score by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-CRP Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the DAS28-CRP score by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-CRP Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Simplified Disease Activity Index (SDAI) Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the SDAI was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28‚Äêjoint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] - 10cm [worst]) and level of C-reactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] - 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SDAI by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the SDAI by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28‚Äêjoint assessment), patient and physician global assessment of disease activity (VAS 0 cm [best] - 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SDAI by the Number of DMARD Failures at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the SDAI by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28‚Äêjoint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] - 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SDAI by Duration of Disease at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the SDAI by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28‚Äêjoint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] - 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SDAI by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the SDAI by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28‚Äêjoint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] - 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease with increasing scores indicating increased burden of disease. DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SDAI by Baseline RF Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the SDAI by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] - 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SDAI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the SDAI by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] - 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] - 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SDAI by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the SDAI by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] - 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SDAI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the SDAI by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] - 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SDAI by Physician Experience Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] - 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SDAI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] - 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SDAI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] - 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SDAI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] - 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved DAS28-ESR EULAR Response</measure>
    <time_frame>Month 2, Month 4, Month 6</time_frame>
    <description>EULAR response was assessed at the end of Month 2, Month 4, and Month 6 by the Disease Activity Score using the 28 tender and swollen joint count calculated with erythrocyte sedimentation rate values (DAS28-ESR). A good response would was defined as a decrease &gt;1.2 units and a final DAS28-ESR &lt; 3.2 units, while a moderate response was defined as a decrease &gt; 1.2 units and final DAS28-ESR &gt;= 3.2 units, OR a decrease of 0.6 to 1.2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved DAS28-CRP EULAR Response</measure>
    <time_frame>Month 2, Month 4, Month 6</time_frame>
    <description>DAS28-CRP EULAR response is defined as a good or moderate response that results in a DAS28-CRP &gt;=0.6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6</measure>
    <time_frame>Month 2, Month 4, Month 6</time_frame>
    <description>The number of participants achieving low disease activity or remission was calculated by the DAS28-ESR, DAS28-CRP, and SDAI at study Month 2, Month 4, and Month 6. Low disease activity by DAS28-ESR was defined as &gt;= 2.6 to 3.2, and remission was defined as a DAS28-ESR &lt;2.6. Low disease activity by DAS28-CRP was defined as DAS28-CRP &gt;=2.6 to 3.2, and remission was defined as DAS28-CRP &gt;2.6. Low disease activity by SDAI was defined as SDAI &gt;5.0 to &lt;=20, and remission was defined as SDAI &lt;=5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ-DI) by Concomitant MTX Dose at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline the disability index of the HAQ was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst)with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in HAQ-DI by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the HAQ-DI by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in HAQ-DI by the Number of DMARD Failures at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the HAQ-DI by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in HAQ-DI by Duration of Disease at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the HAQ-DI by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in HAQ-DI by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the HAQ-DI by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in HAQ-DI by Baseline RF Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the HAQ-DI by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in HAQ-DI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the HAQ-DI by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in HAQ-DI by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the HAQ-DI by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in HAQ-DI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the HAQ-DI by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in HAQ-DI by Physician Experience Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in HAQ-DI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in HAQ-DI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a scores ranging from 0 (best) to 3 (best) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in HAQ-DI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved Minimal or Absence of Functional Impairment</measure>
    <time_frame>Month 2, Month 4, Month 6</time_frame>
    <description>The number of participants that achieved minimal or absence of functional impairment as assessed by the HAQ at study Month 2, Month 4, and Month 6 was calculated. Minimal or absence of functional impairment was defined as a HAQ score of &lt;=0.5. The HAQ evaluates participants on a scale of 0 to 3, with 0=with no difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the EuroQOL (EQ-5D) Quality-of-Life Questionnaire by Concomitant MTX Dose at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>Concomitant MTX dose was defined as low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and and high &gt;=15 mg/week. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. DMARD Combination 1=MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2=MTX + leflunomide; Combination 3=MTX +sulfasalazine; Combination 4=MTX + hydrochloroquine, chloroquine, chloroquine phosphate+sulfasalazine; Combination 5=leflunomide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EQ-5D by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the EQ-5D by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EQ-5D by the Number of DMARD Failures at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the EQ-5D by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EQ-5D by Duration of Disease at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the EQ-5D by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EQ-5D by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the EQ-5D by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EQ-5D by Baseline RF Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the EQ-5D by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EQ-5D by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the EQ-5D by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EQ-5D by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the EQ-5D by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EQ-5D by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The mean change from baseline in the EQ-5D by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EQ-5D by Physician Experience Level at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EQ-5D by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EQ-5D by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EQ-5D by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</measure>
    <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
    <description>The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant indicates their health state by ticking the box against the most appropriate statement. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Participant Acceptable Symptom State (PASS) at Month 4, Month 6, and Month 8</measure>
    <time_frame>Month 2, Month 4, Month 6</time_frame>
    <description>The number of participants achieving PASS was evaluated at study Month 2, Month 4, and Month 6 was calculated. PASS is participant self-evaluation tool that uses a VAS 0mm (best) - 100mm (worst), with a score &lt;=31 representing an acceptable PASS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Area Under the DAS28-ESR Curve From Study Month 6 to Month 12</measure>
    <time_frame>End of Month 6, End of Month 12</time_frame>
    <description>The DAS28-ESR is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR, and participant assessment of disease activity measure on a visual analogue scale. The DAS28-ESR has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). Minimum score=0 (best) to maximum score=10 (worst). The DAS28-ESR area under the curve can be calculated from the DAS28-ESR score versus time curve to provide an assessment of changes in disease activity over time.
The area under the DAS28-ESR score versus time curve was computed using the trapezoidal rule and using raw DAS28-ESR score values at Part-2 Baseline, end of Month 12, and at least 2 intermediate time points. The DAS28-ESR area under the curve was then averaged over the total duration (months) and expressed as units on a scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Remission</measure>
    <time_frame>Start of Month 8, Start of Month 9, Start of Month 10, Start of Month 11, End of Month 12</time_frame>
    <description>Remission was defined as achievement of a DAS28-ESR &lt; 2.6.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3366</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>SC-GLM50</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1 of the study, participants received subcutaneous golimumab treatment at a dose of 50 mg once monthly for 6 months in combination with background DMARD treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV GLM 2 mg/kg + GLM50-SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After 6 months of treatment in study Part 1, participants with good or moderate response but not in remission will receive intravenous (IV) golimumab at a dose of 2 mg/kg once monthly for a period of 6 months or until remission is achieved. Participants will receive IV GLM at a dose of 2 mg/kg at the start of Month 7, and then at the start of Month 8 and Month 10 if the subject has not achieved remission at any of these IV administration visits. If remission is achieved, participants were switched to subcutaneous golimumab at a dose of 50 mg once monthly until study end, in combination with background DMARD treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLM50-SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After 6 months of treatment in study Part 1, participants with good or moderate response but not in remission will receive subcutaneous golimumab at a dose of 50 mg once monthly for a period of 6 months, in combination with background DMARD treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SC golimumab</intervention_name>
    <description>Subcutaneous golimumab at a dose of 50 mg administered once monthly.</description>
    <arm_group_label>SC-GLM50</arm_group_label>
    <arm_group_label>IV GLM 2 mg/kg + GLM50-SC</arm_group_label>
    <arm_group_label>GLM50-SC</arm_group_label>
    <other_name>SCH 900259, subcutaneous</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IV golimumab</intervention_name>
    <description>Intravenous golimumab administered up to 3 times (month 7, 8, 10) during a period of 6 months at a dose of 2 mg/kg of body weight.</description>
    <arm_group_label>IV GLM 2 mg/kg + GLM50-SC</arm_group_label>
    <other_name>SCH 900259, intravenous</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For Part 1:

          -  Age &gt;=18 years, either sex, any race.

          -  Diagnosis of RA according to the 1987 revised American College of Rheumatology (ACR)
             criteria.

          -  Active disease despite DMARD treatment

          -  Subject must be taking at least one of the allowed DMARDs, and must be able to
             continue with it during the trial.

          -  Eligibility for anti tumor necrosis factor (TNF) use according to the following
             criteria:

               -  Participant must have failed conventional treatment according to the
                  investigator's opinion OR local guidelines.

               -  Local guidelines regarding safety screening of anti TNF candidates (ie,
                  tuberculosis [TB] screening and other safety screening such as vaccination, if
                  applicable) must be met. Chest X-ray and either a PPD skin test or
                  QuantiFERON¬Æ-TB Gold test are also required.

               -  Anamnesis and physical examination must make the participant eligible for anti
                  TNF use and trial participation according to the investigator's judgment.

        For Part 2:

          -  Participant must have completed Part 1 of this trial.

          -  Participant must have:

               -  good or moderate response to SC golimumab at the end of Month 6 compared to
                  Baseline, AND.

               -  no DAS28 ESR remission.

          -  Both the investigator and the subject must agree to switch the participant's treatment
             to IV administration as may be required in Part 2 of this trial.

          -  The investigator must judge that no safety events (eg, serious adverse events [SAEs],
             serious infections, marked injection-site reactions or intolerance to drug) have
             occurred that could reoccur or aggravate with increased drug exposure.

        Exclusion Criteria:

          -  History of biologic drug use for RA.

          -  Evidence of active TB. or latent TB that is untreated.

          -  Moderate to severe heart failure

          -  Certain inflammatory rheumatic disease other than RA or certain systemic inflammatory
             condition

          -  Allergy to latex
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Ecuador</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Monaco</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </removed_countries>
  <results_reference>
    <citation>Combe B, Dasgupta B, Louw I, Pal S, Wollenhaupt J, Zerbini CA, Beaulieu AD, Schulze-Koops H, Durez P, Yao R, Vastesaeger N, Weng HH; GO-MORE Investigators. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. Ann Rheum Dis. 2014 Aug;73(8):1477-86. doi: 10.1136/annrheumdis-2013-203229. Epub 2013 Jun 5.</citation>
    <PMID>23740226</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2009</study_first_submitted>
  <study_first_submitted_qc>September 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2009</study_first_posted>
  <results_first_submitted>July 18, 2012</results_first_submitted>
  <results_first_submitted_qc>November 8, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 7, 2012</results_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Golimumab 50 mg Subcutaneous (GLM50-SC)</title>
          <description>Participants received GLM50-SC once monthly for a period of 6 months in Study Part 1.</description>
        </group>
        <group group_id="P2">
          <title>Intravenous GLM (IV-GLM) 2 mg/kg + SC GLM 50 mg</title>
          <description>Participants achieving good or moderate response but not in remission at the conclusion of Study Part 1 received IV-GLM at a dose of 2 mg/kg at the start of Month 7, start of Month 8, and start of Month 10 if remission was not achieved at any of these IV administration visits. If remission was achieved, participants were switched subcutaneous golimumab at a dose of 50 mg once monthly.</description>
        </group>
        <group group_id="P3">
          <title>SC-GLM50</title>
          <description>Participants achieving good or moderate response but not in remission at the end of Study Part 1, received subcutaneous golimumab at a dose of 50 mg once monthly for a period of 6 months in Part 2 of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Study Part 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3366"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3086"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="280"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Meet Protocol Eligibility</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study Part 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="250">Good/moderate responders without remission at the end of Part 1 were invited to enroll in Part 2.</participants>
                <participants group_id="P3" count="255">Good/moderate responders without remission at the end of Part 1 were invited to enroll in Part 2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="212"/>
                <participants group_id="P3" count="238"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Meet Protocol Eligibility</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GLM50-SC</title>
          <description>Participants received 50 mg of golimumab subcutaneously once monthly for a period of 6 months. 3280 enrolled participants were included in the Efficacy-Evaluable population; baseline characteristics are presented for this population.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3280"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="18" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2716"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response at Month 6</title>
        <description>EULAR response was assessed at the end of Month 6 by the Disease Activity Score using the 28 tender and swollen joint count calculated with erythrocyte sedimentation rate values (DAS28-ESR). A good response was defined as a decrease &gt;1.2 units and a final DAS28-ESR &lt; 3.2 units, while a moderate response was defined as a decrease &gt; 1.2 units and final DAS28-ESR &gt;= 3.2 units, OR a decrease of 0.6 to 1.2 units AND final DAS28-ESR &lt;= 5.1 units</description>
        <time_frame>Month 6</time_frame>
        <population>The Efficacy Evaluable population in Part 1 of the study excluded participants without a DAS28-ESR at baseline and at least 1 post-line value DAS28-ESR or those that had very poor data quality due to incomplete documentation.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response at Month 6</title>
          <description>EULAR response was assessed at the end of Month 6 by the Disease Activity Score using the 28 tender and swollen joint count calculated with erythrocyte sedimentation rate values (DAS28-ESR). A good response was defined as a decrease &gt;1.2 units and a final DAS28-ESR &lt; 3.2 units, while a moderate response was defined as a decrease &gt; 1.2 units and final DAS28-ESR &gt;= 3.2 units, OR a decrease of 0.6 to 1.2 units AND final DAS28-ESR &lt;= 5.1 units</description>
          <population>The Efficacy Evaluable population in Part 1 of the study excluded participants without a DAS28-ESR at baseline and at least 1 post-line value DAS28-ESR or those that had very poor data quality due to incomplete documentation.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at the Start of Month 11 and End of Month 12</title>
        <description>The number of participants experiencing DAS28-ESR remission was evaluated at the start of study Month 11 and the end of study Month 12. The DAS28-ESR is expressed on a unit on a scale with the minimum score=0 (best) to maximum score=10 (worst). Remission was defined as DAS28-ESR &lt;2.6.</description>
        <time_frame>Start of Month 11, End of Month 12</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR.</population>
        <group_list>
          <group group_id="O1">
            <title>IV-GLM2/SC-GLM50</title>
            <description>Intravenous golimumab 2 mg/kg followed by subcutaneous golimumab 50 mg once monthly.</description>
          </group>
          <group group_id="O2">
            <title>SC-GLM50</title>
            <description>Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at the Start of Month 11 and End of Month 12</title>
          <description>The number of participants experiencing DAS28-ESR remission was evaluated at the start of study Month 11 and the end of study Month 12. The DAS28-ESR is expressed on a unit on a scale with the minimum score=0 (best) to maximum score=10 (worst). Remission was defined as DAS28-ESR &lt;2.6.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Month 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Swollen Joints by Concomitant Methotrexate (MTX) Dose at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the mean number of swollen joints was calculated at study Month 2, Month 4, and Month 6 by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week). A total of 28 joints were evaluated.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Swollen Joints by Concomitant Methotrexate (MTX) Dose at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the mean number of swollen joints was calculated at study Month 2, Month 4, and Month 6 by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week). A total of 28 joints were evaluated.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Swollen Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low MTX Dose - Month 2 (n =142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 4 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 6 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="5.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 2 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 4 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 6 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 2 (n=1995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 4 (n=1995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="5.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 6 (n=1995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="5.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of swollen joints was calculated by participant baseline background DMARD treatment regimen at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of swollen joints was calculated by participant baseline background DMARD treatment regimen at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Swollen Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DMARD Combination 1 - Month 2 (n=1681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 4 (n=1681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="5.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 6 (n=1681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="5.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 2 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="4.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 4 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 6 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 2 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 4 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="5.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 6 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="5.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 2 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="4.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 -Month 4 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="5.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 6 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 2 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 4 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="4.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 6 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="4.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 2 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 4 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 6 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="4.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Swollen Joints by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of swollen joints by participant baseline concomitant corticosteroid treatment was calculated at study Month 2, Month 4, and Month 6 . A total of 28 joints were evaluated.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Swollen Joints by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of swollen joints by participant baseline concomitant corticosteroid treatment was calculated at study Month 2, Month 4, and Month 6 . A total of 28 joints were evaluated.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Swollen Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did Not Receive Corticosteroids - Month 2 (n=1202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 4 (n=1202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="4.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 6 (n=1202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 2 (n=2078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="4.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 4 (n=2078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 6 (n=2078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="5.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Swollen Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the mean number of swollen joints by the number of baseline participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Swollen Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the mean number of swollen joints by the number of baseline participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Swollen Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failed 1 DMARD - Month 2 (n=1129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="4.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 4 (n=1129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 6 (n=1129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="5.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 2 (n=1176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 4 (n=1176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 6 (n=1176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 2 (n=974)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 4 (n=974)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 6 (n=974)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" spread="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Swollen Joints by Duration of Disease at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the mean number of swollen joints was calculated by the participant duration of disease at study Month 2, Month 4, and Month 6. The participant duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. A total of 28 joints were evaluated.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Swollen Joints by Duration of Disease at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the mean number of swollen joints was calculated by the participant duration of disease at study Month 2, Month 4, and Month 6. The participant duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. A total of 28 joints were evaluated.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Swollen Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Duration &lt; 2 years - Month 2 (n=899)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 4 (n= 899)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 6 (n=899)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 2 (n=764)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 4 (n=764)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 6 (n=764)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 2 (n=692)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="4.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 4 (n=692)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="4.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 6 (n=692)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="5.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 2 (n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 4 (n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="4.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 6 (n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Swollen Joints by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of swollen joints by participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6 by the participant's level of baseline disease activity, as measured by DAS28-ESR. A total of 28 joints were evaluated. DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Swollen Joints by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of swollen joints by participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6 by the participant's level of baseline disease activity, as measured by DAS28-ESR. A total of 28 joints were evaluated. DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Swollen Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 2 (n=698)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 4 (n=698)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 6 (n=698)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 2 (n=2572)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 4 (n=2572)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 6 (n=2572)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="5.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Swollen Joints by Baseline Rheumatoid Factor (RF) Level at Month 2, Month 4, and Month 6</title>
        <description>The change from baseline in the mean number of swollen joints was calculated by the participant baseline level of RF at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Swollen Joints by Baseline Rheumatoid Factor (RF) Level at Month 2, Month 4, and Month 6</title>
          <description>The change from baseline in the mean number of swollen joints was calculated by the participant baseline level of RF at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Swollen Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RF &lt;=22 IU/mL - Month 2 (n=1026)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="4.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 4 (n=1026)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 6 (n=1026)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="5.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 2 (n=1081)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="4.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 4 (n=1081)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 6 (n=1081)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 2 (n=1127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 4 (n=1127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 6 (n=1127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Swollen Joints by Baseline Anti-Cyclic Citrullinated Antibody (Anti-CCP) Level at Month 2, Month 4, and Month 6</title>
        <description>The change from baseline in the mean number of swollen joints was calculated by the participant baseline level of anti-CCP at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Swollen Joints by Baseline Anti-Cyclic Citrullinated Antibody (Anti-CCP) Level at Month 2, Month 4, and Month 6</title>
          <description>The change from baseline in the mean number of swollen joints was calculated by the participant baseline level of anti-CCP at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Swollen Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 2 (n=1038)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 4 (n=1038)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 6 (n=1038)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="5.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 2 (n=1112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 4 (n=1112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="4.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 6 (n=1112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 2 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="4.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 4 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="5.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 6 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6</title>
        <description>The change from baseline in the mean number of swollen joints was calculated by the baseline participant smoking status at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6</title>
          <description>The change from baseline in the mean number of swollen joints was calculated by the baseline participant smoking status at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Swollen Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoker - Month 2 (n=1963)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="4.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 4 (n=1963)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="5.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 6 (n=1963)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 2 (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 4 (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 6 (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 2 (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 4 (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="4.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 6 (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 2 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="4.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 4 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="4.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 pack/day - Month 6 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" spread="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 2 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 4 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 6 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 2 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 4 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 6 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 2 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 4 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 6 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 2 (n=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 4 (n=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 6 (n=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 2 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 4 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 6 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Swollen Joints by Eligibility for Anti-Tumor Necrosis Factor (Anti-TNF) Treatment at Month 2, Month 4, and Month 6</title>
        <description>The change from baseline in the mean number of swollen joints was calculated by the baseline participant eligibility for anti-TNF treatment at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Swollen Joints by Eligibility for Anti-Tumor Necrosis Factor (Anti-TNF) Treatment at Month 2, Month 4, and Month 6</title>
          <description>The change from baseline in the mean number of swollen joints was calculated by the baseline participant eligibility for anti-TNF treatment at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Swollen Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 2 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 4 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 6 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 2 (n=3174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 4 (n=3174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="5.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 6 (n=3174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="5.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Swollen Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of swollen joints was calculated by the participant baseline expectation of treatment outcome at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Swollen Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of swollen joints was calculated by the participant baseline expectation of treatment outcome at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
          <units>Swollen Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=1.5 - Month 2 (n=1212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 4 (n=1212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 6 (n=1212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="5.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 2 (n=1009)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 4 (n=1009)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 6 (n=1009)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="5.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 2 (n=1054)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 4 (n=1054)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 6 (n=1054)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of swollen joints was calculated by the physician experience level at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of swollen joints was calculated by the physician experience level at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Swollen Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=10 years - Month 2 (n=1305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="4.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 4 (n=1305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="4.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 6 (n =1305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 2 (n=1105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 4 (n=1105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 6 (n=1105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 2 (n=850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 4 (n=850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 6 (n=850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="5.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of swollen joints was calculated by the physician experience level with biologics at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of swollen joints was calculated by the physician experience level with biologics at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Swollen Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 to 6 years - Month 2 (n=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="4.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 4 (n=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 6 (n=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 2 (n=1745)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 4 (n=1745)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 6 (n=1745)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 2 (n=355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="4.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 4 (n=355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 6 (n=355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" spread="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Swollen Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of swollen joints was calculated by the baseline number of patients the physician treats with biologics at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. The number of patients treated with biologics is defined as the number of patients treated by the physician in the last month with biologics for rheumatoid arthritis.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Swollen Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of swollen joints was calculated by the baseline number of patients the physician treats with biologics at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. The number of patients treated with biologics is defined as the number of patients treated by the physician in the last month with biologics for rheumatoid arthritis.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Swollen Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-17 patients in prior month - Month 2 (n=1056)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 4 (n=1056)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 6 (n=1056)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.4" spread="5.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 2 (n=1061)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="4.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 4 (n=1061)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 6 (n=1061)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 2 (n=1097)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 4 (n=1097)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 6 (n=1097)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Swollen Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of swollen joints was calculated by the physician's expectation of treatment outcome at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. The physician's expectation of treatment outcomes was assessed at the start of Month 4 at which time physicians were asked to rate their expectations of treatment outcome in each participant as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Swollen Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of swollen joints was calculated by the physician's expectation of treatment outcome at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. The physician's expectation of treatment outcomes was assessed at the start of Month 4 at which time physicians were asked to rate their expectations of treatment outcome in each participant as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Swollen Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High disease activity - Month 2 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 4 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 6 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 2 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 4 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="4.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 6 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 2 (n=1932)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 4 (n=1932)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 6 (n=1932)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 2 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 4 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 6 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Tender Joints by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of tender joints was calculated by participant concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Tender Joints by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of tender joints was calculated by participant concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low MTX Dose - Month 2 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 4 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 6 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="6.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 2 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 4 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 6 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.1" spread="6.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 2 (n=1995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="5.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 4 (n=1995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="6.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 6 (n=1995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="6.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of tender joints was calculated by participant background DMARD treatment at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of tender joints was calculated by participant background DMARD treatment at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DMARD Combination 1 - Month 2 (n=1681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 4 (n=1681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 6 (n=1681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 2 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="6.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 4 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="6.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 6 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="6.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 2 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="6.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 4 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="6.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 6 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 2 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="6.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 -Month 4 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="6.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 6 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="7.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 2 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="5.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 4 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="5.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 6 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 2 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="5.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 4 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="6.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 6 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Tender Joints by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of tender joints was calculated by participant baseline concomitant steroid treatment at study Month 2, Month 4, and Month 6. A total 28 joints were evaluated.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Tender Joints by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of tender joints was calculated by participant baseline concomitant steroid treatment at study Month 2, Month 4, and Month 6. A total 28 joints were evaluated.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did Not Receive Corticosteroids - Month 2 (n=1202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="5.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 4 (n=1202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 6 (n=1202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="6.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 2 (n=2078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 4 (n=2078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="6.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 6 (n=2078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="6.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Tender Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of tender joints was calculated by the number of participant DMARD failures at baseline at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Tender Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of tender joints was calculated by the number of participant DMARD failures at baseline at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failed 1 DMARD - Month 2 (n=1129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="5.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 4 (n=1129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="6.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 6 (n=1129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="6.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 2 (n=1176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 4 (n=1176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="6.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 6 (n=1176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="6.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 2 (n=974)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 4 (n=974)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="6.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 6 (n=974)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="6.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Tender Joints by Duration of Disease at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of tender joints was calculated by the participant duration of disease at study Month 2, Month 4, and Month 6. Duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. A total of 28 joints were evaluated.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Tender Joints by Duration of Disease at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of tender joints was calculated by the participant duration of disease at study Month 2, Month 4, and Month 6. Duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. A total of 28 joints were evaluated.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Duration &lt; 2 years - Month 2 (n=899)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 4 (n=899)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.4" spread="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 6 (n=899)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="6.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 2 (n=764)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 4 (n=764)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="6.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 6 (n=764)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="6.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 2 (n=692)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 4 (n=692)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="6.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 6 (n=692)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="6.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 2 (n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="5.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 4 (n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 6 (n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Tender Joints by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of tender joints was calculated by the participant baseline level of disease activity, as measured by DAS28, at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Tender Joints by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of tender joints was calculated by the participant baseline level of disease activity, as measured by DAS28, at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 2 (n=698)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="4.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 4 (n=698)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 6 (n=698)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 2 (n=2572)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 4 (n=2572)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="6.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 6 (n=2572)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.9" spread="6.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Tender Joints by Baseline RF Level at Month 2, Month 4, and Month 6</title>
        <description>The change from baseline in the mean number of tender joints was calculated by the participant baseline level of RF at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Tender Joints by Baseline RF Level at Month 2, Month 4, and Month 6</title>
          <description>The change from baseline in the mean number of tender joints was calculated by the participant baseline level of RF at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RF &lt;=22 IU/mL - Month 2 (n=1026)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 4 (n=1026)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="6.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 6 (n=1026)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="6.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 2 (n=1081)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 4 (n=1081)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="6.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 6 (n=1081)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 2 (n=1127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="6.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 4 (n=1127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="6.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 6 (n=1127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.3" spread="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Tender Joints by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of tender joints was calculated by the participant baseline level of anti-CCP at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Tender Joints by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of tender joints was calculated by the participant baseline level of anti-CCP at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 2 (n=1038)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 4 (n=1038)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="6.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 6 (n=1038)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 2 (n=1112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="5.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 4 (n=1112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 6 (n=1112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="6.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 2 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 4 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="6.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 6 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="6.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of tender joints was calculated by the baseline participant smoking status at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of tender joints was calculated by the baseline participant smoking status at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoker - Month 2 (n=1963)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 4 (n=1963)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="6.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 6 (n=1963)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="6.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 2 (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 4 (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.4" spread="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 6 (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="6.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 2 (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="5.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 4 (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 6 (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="6.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 2 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="5.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 4 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 pack/day - Month 6 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="6.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 2 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 4 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 6 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="6.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 2 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="6.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 4 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="6.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 6 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 2 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 4 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="6.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 6 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="6.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 2 (n=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 4 (n=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="6.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 6 (n=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="6.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 2 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 4 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="6.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 6 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="6.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Tender Joints by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of tender joints was calculated by the baseline participant eligibility for anti-TNF treatment at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Tender Joints by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of tender joints was calculated by the baseline participant eligibility for anti-TNF treatment at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 2 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 4 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 6 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="5.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 2 (n=3174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 4 (n=3174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="6.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 6 (n=3174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="6.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Tender Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of tender joints was calculated by the participant baseline expectation of treatment outcome at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Tender Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of tender joints was calculated by the participant baseline expectation of treatment outcome at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
          <units>Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=1.5 - Month 2 (n=1212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 4 (n=1212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="6.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 6 (n=1212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="6.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 2 (n=1009)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="5.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 4 (n=1009)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 6 (n=1009)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="6.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 2 (n=1054)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 4 (n=1054)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 6 (n=1054)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of tender joints was calculated by the physician experience level at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of tender joints was calculated by the physician experience level at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=10 years - Month 2 (n=1305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 4 (n=1305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 6 (n=1305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 2 (n=1105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 4 (n=1105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="6.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 6 (n=1105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="6.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 2 (n=850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="5.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 4 (n=850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="6.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 6 (n=850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of tender joints was calculated by the physician experience level with biologics at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of tender joints was calculated by the physician experience level with biologics at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 to 6 years - Month 2 (n=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="5.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 4 (n=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="6.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 6 (n=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="6.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 2 (n=1745)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 4 (n=1745)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="6.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 6 (n=1745)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="6.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 2 (n=355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 4 (n=355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.4" spread="6.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 6 (n=355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="6.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Tender Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of tender joints was calculated by the baseline number of patients the physician treats with biologics at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. The number of patients treated with biologics is defined as the number of patients treated by the physician in the last month with biologics for rheumatoid arthritis.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Tender Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of tender joints was calculated by the baseline number of patients the physician treats with biologics at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. The number of patients treated with biologics is defined as the number of patients treated by the physician in the last month with biologics for rheumatoid arthritis.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-17 patients in prior month - Month 2 (n=1056)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 4 (n=1056)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 6 (n=1056)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="6.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 2 (n=1061)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="5.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 4 (n=1061)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="6.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 6 (n=1061)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="6.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 2 (n=1097)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="5.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 4 (n=1097)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="6.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 6 (n=1097)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="6.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Tender Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the number of tender joints. was calculated by the physician's expectation of treatment outcome at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. The physician's expectation of treatment outcomes was assessed at the start of Month 4 at which time physicians were asked to rate their expectations of treatment outcome in each participant as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Tender Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the number of tender joints. was calculated by the physician's expectation of treatment outcome at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. The physician's expectation of treatment outcomes was assessed at the start of Month 4 at which time physicians were asked to rate their expectations of treatment outcome in each participant as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High disease activity - Month 2 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 4 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 6 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.4" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 2 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 4 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="6.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 6 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="6.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 2 (n=1932)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 4 (n=1932)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 6 (n=1932)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="6.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 2 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 4 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="6.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 6 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant global assessment of disease activity was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a visual analogue scale (VAS; 0mm [best] -100mm [worst]) with increasing scores indicating increased level of disease.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant global assessment of disease activity was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a visual analogue scale (VAS; 0mm [best] -100mm [worst]) with increasing scores indicating increased level of disease.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low MTX Dose - Month 2 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.1" spread="24.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 4 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.3" spread="26.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 6 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.9" spread="29.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 2 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.6" spread="22.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 4 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.9" spread="24.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 6 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.4" spread="27.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 2 (n=1995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.3" spread="25.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 4 (n=1995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.2" spread="27.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 6 (n=1995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.0" spread="28.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
        <description>The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
          <description>The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DMARD Combination 1 - Month 2 (n=1681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.2" spread="24.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 4 (n=1681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.5" spread="27.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 6 (n=1681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.7" spread="28.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 2 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.2" spread="24.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 4 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.4" spread="27.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 6 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.8" spread="29.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 2 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.8" spread="25.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 4 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.8" spread="28.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 6 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.4" spread="28.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 2 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.3" spread="25.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 -Month 4 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.2" spread="24.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 6 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.1" spread="28.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 2 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.1" spread="23.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 4 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.3" spread="24.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 6 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.9" spread="28.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 2 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.8" spread="24.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 4 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.5" spread="28.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 6 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.5" spread="29.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the participant global assessment of disease activity by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the participant global assessment of disease activity by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did Not Receive Corticosteroids - Month 2 (n=1202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.5" spread="23.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 4 (n=1202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.0" spread="26.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 6 (n=1202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.2" spread="28.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 2 (n=2078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.3" spread="25.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 4 (n=2078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.4" spread="27.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 6 (n=2078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.7" spread="28.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the participant global assessment of disease activity score by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the participant global assessment of disease activity score by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failed 1 DMARD - Month 2 (n=1129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.9" spread="23.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 4 (n=1129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.1" spread="28.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 6 (n=1129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.9" spread="29.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 2 (n=1176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.8" spread="24.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 4 (n=1176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.1" spread="26.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 6 (n=1176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.1" spread="28.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 2 (n=974)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.3" spread="23.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 4 (n=974)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.8" spread="26.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 6 (n=974)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.4" spread="27.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the participant global assessment of disease activity by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the participant global assessment of disease activity by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Duration &lt; 2 years - Month 2 (n=899)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.4" spread="25.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 4 (n=899)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.6" spread="28.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 6 (n=899)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.5" spread="29.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 2 (n=764)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.9" spread="24.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 4 (n=764)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.9" spread="27.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 6 (n=764)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.9" spread="28.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 2 (n=692)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.2" spread="24.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 4 (n=692)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.8" spread="26.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 6 (n=692)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.2" spread="28.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 2 (n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.8" spread="23.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 4 (n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.3" spread="26.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 6 (n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.8" spread="27.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the participant global assessment of disease activity by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the participant global assessment of disease activity by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 2 (n=698)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.0" spread="23.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 4 (n=698)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.0" spread="26.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 6 (n=698)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.6" spread="27.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 2 (n=2572)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.4" spread="24.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 4 (n=2572)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.5" spread="27.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 6 (n=2572)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.3" spread="28.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the participant global assessment of disease activity by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the participant global assessment of disease activity by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RF &lt;=22 IU/mL - Month 2 (n=1026)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" spread="24.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 4 (n=1026)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.7" spread="27.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 6 (n=1026)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.6" spread="28.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 2 (n=1081)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.7" spread="24.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 4 (n=1081)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.7" spread="26.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 6 (n=1081)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.5" spread="28.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 2 (n=1127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.2" spread="24.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 4 (n=1127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.6" spread="26.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 6 (n=1127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.2" spread="28.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the participant global assessment of disease activity by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the participant global assessment of disease activity by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 2 (n=1038)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.2" spread="24.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 4 (n=1038)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.3" spread="27.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 6 (n=1038)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.4" spread="28.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 2 (n=1112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.6" spread="25.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 4 (n=1112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.1" spread="27.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 6 (n=1112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.7" spread="28.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 2 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.1" spread="23.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 4 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.4" spread="26.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 6 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.3" spread="28.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the participant global assessment of disease activity by participant baseline smoking status was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the participant global assessment of disease activity by participant baseline smoking status was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoker - Month 2 (n=1963)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.7" spread="24.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 4 (n=1963)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.3" spread="26.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 6 (n=1963)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.5" spread="27.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 2 (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.1" spread="25.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 4 (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.2" spread="27.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 6 (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.9" spread="28.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 2 (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.2" spread="24.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 4 (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.5" spread="27.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 6 (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.2" spread="27.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 2 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.5" spread="23.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 4 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.0" spread="27.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 pack/day - Month 6 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.3" spread="29.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 2 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.3" spread="24.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 4 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.7" spread="27.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 6 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.3" spread="30.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 2 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.9" spread="29.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 4 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.7" spread="31.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 6 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.8" spread="29.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 2 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.9" spread="25.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 4 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.4" spread="27.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 6 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.8" spread="28.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 2 (n=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.4" spread="24.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 4 (n=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.3" spread="26.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 6 (n=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.4" spread="29.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 2 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.6" spread="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 4 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.2" spread="28.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 6 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.3" spread="28.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the participant global assessment of disease activity by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the participant global assessment of disease activity by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 2 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.9" spread="21.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 4 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.7" spread="24.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 6 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.8" spread="27.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 2 (n=3174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.0" spread="24.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 4 (n=3174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.7" spread="27.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 6 (n=3174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.3" spread="28.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the participant global assessment of disease activity by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the participant global assessment of disease activity by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=1.5 - Month 2 (n=1212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.9" spread="25.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 4 (n=1212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.5" spread="28.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 6 (n=1212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.9" spread="28.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 2 (n=1009)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.3" spread="24.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 4 (n=1009)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.0" spread="27.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 6 (n=1009)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.3" spread="28.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 2 (n=1054)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.3" spread="22.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 4 (n=1054)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.8" spread="25.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 6 (n=1054)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.6" spread="27.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the participant global assessment of disease activity by the treating physician level of experience was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the participant global assessment of disease activity by the treating physician level of experience was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=10 years - Month 2 (n=1305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.0" spread="24.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 4 (n=1305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.2" spread="26.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 6 (n=1305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.6" spread="28.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 2 (n=1105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.8" spread="24.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 4 (n=1105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.5" spread="26.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 6 (n=1105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.1" spread="28.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 2 (n=850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.3" spread="25.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 4 (n=850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.2" spread="28.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 6 (n=850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.8" spread="28.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>mm [Best]Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the participant global assessment of disease activity by physician experience level with biologics was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>mm [Best]Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the participant global assessment of disease activity by physician experience level with biologics was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 to 6 years - Month 2 (n=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.2" spread="24.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 4 (n=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.8" spread="25.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 6 (n=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.4" spread="27.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 2 (n=1745)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.9" spread="24.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 4 (n=1745)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.5" spread="27.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 6 (n=1745)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.8" spread="29.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 2 (n=355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.5" spread="24.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 4 (n=355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.3" spread="28.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 6 (n=355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.2" spread="28.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the participant global assessment of disease activity by the number of patients treated with biologics by the treating physician was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the participant global assessment of disease activity by the number of patients treated with biologics by the treating physician was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-17 patients in prior month - Month 2 (n=1056)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.0" spread="23.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 4 (n=1056)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.3" spread="25.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 6 (n=1056)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.4" spread="27.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 2 (n=1061)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.8" spread="24.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 4 (n=1061)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.7" spread="27.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 6 (n=1061)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.8" spread="28.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 2 (n=1097)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.2" spread="25.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 4 (n=1097)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.0" spread="28.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 6 (n=1097)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.3" spread="29.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the participant global assessment of disease activity by the physician's expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Participant Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the participant global assessment of disease activity by the physician's expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] ‚Äì 100mm [worst]) with increasing scores indicating increased level of disease. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High disease activity - Month 2 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.1" spread="25.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 4 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.4" spread="24.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 6 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.6" spread="27.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 2 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.3" spread="24.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 4 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.4" spread="27.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 6 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.3" spread="27.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 2 (n=1932)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.4" spread="24.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 4 (n=1932)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.3" spread="27.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 6 (n=1932)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.0" spread="28.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 2 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.2" spread="25.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 4 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.5" spread="27.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 6 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.9" spread="29.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Erythrocyte Sedimentation Rate (ESR) by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
        <description>The change from baseline in participant serum ESR was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Erythrocyte Sedimentation Rate (ESR) by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
          <description>The change from baseline in participant serum ESR was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low MTX Dose - Month 2 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="14.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 4 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="18.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 6 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="21.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 2 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.2" spread="17.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 4 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" spread="21.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 6 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.8" spread="22.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 2 (n=1995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="17.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 4 (n=1995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="19.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 6 (n=1995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="20.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum ESR by concomitant DMARD background treatment was calculated at study Month 2, Month 4, and Month 6. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum ESR by concomitant DMARD background treatment was calculated at study Month 2, Month 4, and Month 6. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DMARD Combination 1 - Month 2 (n=1681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="17.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 4 (n=1681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="18.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 6 (n=1681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.6" spread="20.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 2 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="19.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 4 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="20.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 6 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="22.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 2 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="20.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 4 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.9" spread="19.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 6 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="22.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 2 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 -Month 4 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.9" spread="23.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 6 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" spread="21.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 2 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="18.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 4 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="19.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 6 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="20.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 2 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="17.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 4 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="20.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 6 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="21.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in ESR by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in serum ESR by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in ESR by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in serum ESR by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did Not Receive Corticosteroids - Month 2 (n=1202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.3" spread="16.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 4 (n=1202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.4" spread="18.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 6 (n=1202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.7" spread="20.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 2 (n=2078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="18.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 4 (n=2078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="20.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 6 (n=2078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.7" spread="21.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in ESR by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum ESR by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in ESR by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum ESR by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failed 1 DMARD - Month 2 (n=1129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="17.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 4 (n=1129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" spread="20.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 6 (n=1129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.0" spread="21.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 2 (n=1176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="18.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 4 (n=1176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="19.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 6 (n=1176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="20.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 2 (n=974)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.1" spread="17.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 4 (n=974)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.5" spread="18.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 6 (n=974)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.9" spread="20.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in ESR by Duration of Disease at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the participant serum ESR by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in ESR by Duration of Disease at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the participant serum ESR by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Duration &lt; 2 years - Month 2 (n=899)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="17.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 4 (n=899)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" spread="20.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 6 (n=899)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.2" spread="21.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 2 (n=764)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.1" spread="17.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 4 (n=764)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.5" spread="19.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 6 (n=764)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="20.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 2 (n=692)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.5" spread="17.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 4 (n=692)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="18.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 6 (n=692)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.4" spread="21.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 2 (n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="17.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 4 (n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" spread="19.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 6 (n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="20.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in ESR by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum ESR by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in ESR by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum ESR by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 2 (n=698)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="11.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 4 (n=698)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="13.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 6 (n=698)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="13.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 2 (n=2572)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.1" spread="18.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 4 (n=2572)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" spread="20.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 6 (n=2572)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.1" spread="22.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in ESR by Baseline RF Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum ESR by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in ESR by Baseline RF Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum ESR by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RF &lt;=22 IU/mL - Month 2 (n=1026)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="17.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 4 (n=1026)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="18.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 6 (n=1026)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="19.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 2 (n=1081)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="17.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 4 (n=1081)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="19.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 6 (n=1081)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="20.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 2 (n=1127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="18.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 4 (n=1127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.1" spread="20.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 6 (n=1127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="22.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in ESR by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in ESR by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in ESR by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in ESR by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 2 (n=1038)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="16.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 4 (n=1038)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="17.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 6 (n=1038)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="20.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 2 (n=1112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="18.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 4 (n=1112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.7" spread="20.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 6 (n=1112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.0" spread="20.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 2 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="18.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 4 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.1" spread="20.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 6 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.4" spread="22.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum ESR by participant baseline smoking status was calculated at study Month 2, Month 4, and Month 6. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum ESR by participant baseline smoking status was calculated at study Month 2, Month 4, and Month 6. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoker - Month 2 (n=1963)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="18.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 4 (n=1963)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.8" spread="20.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 6 (n=1963)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.7" spread="21.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 2 (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="18.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 4 (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" spread="19.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 6 (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="20.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 2 (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="17.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 4 (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="18.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 6 (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.9" spread="20.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 2 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.3" spread="17.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 4 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="19.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 pack/day - Month 6 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.7" spread="22.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 2 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="14.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 4 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="18.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 6 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="18.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 2 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="12.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 4 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="16.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 6 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="20.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 2 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.1" spread="17.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 4 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="18.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 6 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="21.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 2 (n=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="16.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 4 (n=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="18.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 6 (n=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="18.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 2 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="16.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 4 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="19.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 6 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="20.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in ESR by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum ESR by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in ESR by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum ESR by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 2 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="10.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 4 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="10.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 6 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="11.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 2 (n=3174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.5" spread="17.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 4 (n=3174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.4" spread="19.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 6 (n=3174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="21.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in ESR by Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum ESR by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in ESR by Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum ESR by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=1.5 - Month 2 (n=1212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="18.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 4 (n=1212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.2" spread="19.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 6 (n=1212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.4" spread="21.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 2 (n=1009)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="18.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 4 (n=1009)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.3" spread="20.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 6 (n=1009)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="21.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 2 (n=1054)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="16.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 4 (n=1054)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="18.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 6 (n=1054)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="19.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in ESR by Physician Experience Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum ESR by the treating physician level of experience was evaluated at study Month 2, Month 4, and Month 6. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in ESR by Physician Experience Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum ESR by the treating physician level of experience was evaluated at study Month 2, Month 4, and Month 6. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=10 years - Month 2 (n=1305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="17.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 4 (n=1305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="19.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 6 (n=1305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.9" spread="20.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 2 (n=1105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="18.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 4 (n=1105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.7" spread="20.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 6 (n=1105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="22.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 2 (n=850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="17.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 4 (n=850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="19.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 6 (n=850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" spread="19.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in ESR by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum ESR by physician experience level with biologics was evaluated at study Month 2, Month 4, and Month 6. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in ESR by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum ESR by physician experience level with biologics was evaluated at study Month 2, Month 4, and Month 6. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 to 6 years - Month 2 (n=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="18.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 4 (n=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.7" spread="19.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 6 (n=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.9" spread="21.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 2 (n=1745)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="17.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 4 (n=1745)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="19.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 6 (n=1745)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.0" spread="20.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 2 (n=355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="17.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 4 (n=355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" spread="18.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 6 (n=355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.0" spread="19.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in ESR by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum ESR by the number of patients treated with biologics by the treating physician was evaluated at study Month 2, Month 4, and Month 6. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in ESR by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum ESR by the number of patients treated with biologics by the treating physician was evaluated at study Month 2, Month 4, and Month 6. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-17 patients in prior month - Month 2 (n=1056)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="18.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 4 (n=1056)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="19.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 6 (n=1056)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.5" spread="20.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 2 (n=1061)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="16.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 4 (n=1061)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="19.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 6 (n=1061)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" spread="21.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 2 (n=1097)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="17.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 4 (n=1097)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="19.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 6 (n=1097)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="21.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum ESR by the physician's expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum ESR by the physician's expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High disease activity - Month 2 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.9" spread="20.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 4 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.0" spread="23.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 6 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.0" spread="26.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 2 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="19.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 4 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="20.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 6 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.6" spread="21.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 2 (n=1932)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.3" spread="17.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 4 (n=1932)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="19.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 6 (n=1932)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" spread="20.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 2 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="17.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 4 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="19.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 6 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="21.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in C-Reactive Protein (CRP) by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
        <description>The change from baseline in participant serum CRP was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in C-Reactive Protein (CRP) by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
          <description>The change from baseline in participant serum CRP was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low MTX Dose - Month 2 (n=138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.43" spread="15.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 4 (n=138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.97" spread="19.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 6 (n=138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.61" spread="17.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 2 (n=519)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.14" spread="17.591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 4 (n=519)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.54" spread="20.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 6 (n=519)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.93" spread="23.755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 2 (n=1967)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.52" spread="18.452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 4 (n=1967)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.46" spread="18.921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 6 (n=1967)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.76" spread="19.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum CRP by concomitant DMARD background treatment was calculated at study Month 2, Month 4, and Month 6. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum CRP by concomitant DMARD background treatment was calculated at study Month 2, Month 4, and Month 6. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DMARD Combination 1 - Month 2 (n=1662)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.02" spread="16.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 4 (n=1662)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.74" spread="18.459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 6 (n=1662)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.91" spread="19.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 2 (n=424)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.14" spread="16.979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 4 (n=424)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.07" spread="21.648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 6 (n=424)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.43" spread="18.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 2 (n=211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.56" spread="22.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 4 (n=211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.32" spread="19.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 6 (n=211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.37" spread="16.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 2 (n=147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.57" spread="22.433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 -Month 4 (n=147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.61" spread="22.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 6 (n=147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.54" spread="22.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 2 (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.42" spread="28.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 4 (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.49" spread="16.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 6 (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.62" spread="36.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 2 (n=301)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.90" spread="16.817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 4 (n=301)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.70" spread="17.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 6 (n=301)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.08" spread="19.620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CRP by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in serum CRP by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CRP by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in serum CRP by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did Not Receive Corticosteroids - Month 2 (n=1187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.14" spread="15.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 4 (n=1187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.90" spread="15.643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 6 (n=1187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.00" spread="18.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 2 (n=2048)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.04" spread="19.355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 4 (n=2048)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.98" spread="20.850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 6 (n=2048)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.20" spread="20.738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CRP by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum CRP by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CRP by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum CRP by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failed 1 DMARD - Month 2 (n=1118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.38" spread="18.525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 4 (n=1118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.23" spread="20.809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 6 (n=1118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.06" spread="21.514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 2 (n=1158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.20" spread="17.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 4 (n=1158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.89" spread="18.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 6 (n=1158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.54" spread="18.247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 2 (n=958)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.56" spread="17.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 4 (n=958)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.69" spread="18.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 6 (n=958)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.69" spread="19.959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CRP by Duration of Disease at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the participant serum CRP by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CRP by Duration of Disease at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the participant serum CRP by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Duration &lt; 2 years - Month 2 (n=885)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.84" spread="18.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 4 (n=885)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.40" spread="21.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 6 (n=885)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.03" spread="21.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 2 (n=756)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.42" spread="20.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 4 (n=756)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.23" spread="19.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 6 (n=756)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.15" spread="20.592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 2 (n=681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.73" spread="15.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 4 (n=681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.49" spread="18.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 6 (n=681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.15" spread="16.892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 2 (n=912)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.73" spread="17.183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 4 (n=912)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.05" spread="17.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 6 (n=912)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.63" spread="19.402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CRP by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum CRP by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. DAS28-ESR scores of &gt; 3.2 to &lt;=5.1 indicate moderate disease activity and DAS28-ESR scores of &gt; 5.1 indicate high disease activity.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CRP by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum CRP by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. DAS28-ESR scores of &gt; 3.2 to &lt;=5.1 indicate moderate disease activity and DAS28-ESR scores of &gt; 5.1 indicate high disease activity.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 2 (n=687)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.07" spread="11.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 4 (n=687)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.61" spread="13.582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 6 (n=687)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="13.418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 2 (n=2538)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.43" spread="19.287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 4 (n=2538)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.67" spread="20.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 6 (n=2538)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.89" spread="21.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CRP by Baseline RF Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum CRP by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CRP by Baseline RF Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum CRP by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RF &lt;=22 IU/mL - Month 2 (n=1025)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.18" spread="16.961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 4 (n=1025)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.63" spread="18.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 6 (n=1025)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.19" spread="18.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 2 (n=1079)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.12" spread="15.703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 4 (n=1079)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.89" spread="17.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 6 (n=1079)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.46" spread="21.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 2 (n=1125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.85" spread="20.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 4 (n=1125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.21" spread="21.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 6 (n=1125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.59" spread="20.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CRP by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in CRP by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CRP by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in CRP by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 2 (n=1027)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.16" spread="17.703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 4 (n=1027)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.79" spread="19.454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 6 (n=1027)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.03" spread="18.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 2 (n=1101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.95" spread="17.423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 4 (n=1101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.73" spread="18.955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 6 (n=1101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.60" spread="18.699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 2 (n=1070)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.00" spread="18.651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 4 (n=1070)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.22" spread="19.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 6 (n=1070)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.60" spread="22.345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum CRP by participant baseline smoking status was calculated at study Month 2, Month 4, and Month 6. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum CRP by participant baseline smoking status was calculated at study Month 2, Month 4, and Month 6. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoker - Month 2 (n=1941)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.00" spread="18.946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 4 (n=1941)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.96" spread="20.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 6 (n=1941)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.27" spread="21.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 2 (n=318)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.33" spread="13.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 4 (n=318)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.42" spread="18.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 6 (n=318)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.70" spread="16.922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 2 (n=312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.88" spread="19.794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 4 (n=312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.50" spread="17.869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 6 (n=312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.38" spread="19.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 2 (n=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.28" spread="16.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 4 (n=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.85" spread="18.384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 pack/day - Month 6 (n=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.72" spread="15.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 2 (n=388)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.61" spread="13.870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 4 (n=388)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.88" spread="15.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 6 (n=388)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.57" spread="18.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 2 (n=58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.44" spread="21.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 4 (n=58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" spread="23.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 6 (n=58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.76" spread="19.927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 2 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.13" spread="18.761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 4 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.91" spread="18.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 6 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.75" spread="18.752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 2 (n=450)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.73" spread="13.845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 4 (n=450)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.63" spread="16.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 6 (n=450)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.60" spread="15.440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 2 (n=405)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.92" spread="15.558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 4 (n=405)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.40" spread="18.166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 6 (n=405)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.48" spread="18.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CRP by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum CRP by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CRP by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum CRP by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 2 (n=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.92" spread="10.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 4 (n=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.74" spread="11.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 6 (n=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.16" spread="10.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 2 (n=3130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.81" spread="18.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 4 (n=3130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.68" spread="19.314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 6 (n=3130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.85" spread="20.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CRP by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum CRP by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CRP by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum CRP by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=1.5 - Month 2 (n=1201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.83" spread="15.963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 4 (n=1201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.58" spread="17.902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 6 (n=1201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.83" spread="17.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 2 (n=995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.61" spread="18.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 4 (n=995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.66" spread="21.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 6 (n=995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.47" spread="22.984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 2 (n=1034)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.69" spread="19.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 4 (n=1034)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.51" spread="18.487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 6 (n=1034)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.00" spread="19.364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CRP by Physician Experience Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum CRP by the treating physician level of experience was evaluated at study Month 2, Month 4, and Month 6. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CRP by Physician Experience Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum CRP by the treating physician level of experience was evaluated at study Month 2, Month 4, and Month 6. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=10 years - Month 2 (n=1284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.17" spread="17.628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 4 (n=1284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.29" spread="17.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 6 (n=1284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.77" spread="20.401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 2 (n=1094)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.60" spread="19.412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 4 (n=1094)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.58" spread="20.544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 6 (n=1094)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.65" spread="20.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 2 (n=837)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.71" spread="16.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 4 (n=837)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.03" spread="19.794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 6 (n=837)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.96" spread="18.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CRP by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum CRP by physician experience level with biologics was evaluated at study Month 2, Month 4, and Month 6. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CRP by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum CRP by physician experience level with biologics was evaluated at study Month 2, Month 4, and Month 6. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 to 6 years - Month 2 (n=1147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.40" spread="16.834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 4 (n=1147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.53" spread="18.865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 6 (n=1147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.38" spread="18.656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 2 (n=1717)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.95" spread="18.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 4 (n=1717)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.59" spread="19.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 6 (n=1717)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.42" spread="20.802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 2 (n=351)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.58" spread="18.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 4 (n=351)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.68" spread="17.691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 6 (n=351)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.60" spread="19.623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CRP by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum CRP by the number of patients treated with biologics by the treating physician was evaluated at study Month 2, Month 4, and Month 6. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CRP by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum CRP by the number of patients treated with biologics by the treating physician was evaluated at study Month 2, Month 4, and Month 6. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-17 patients in prior month - Month 2 (n=1043)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.61" spread="17.530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 4 (n=1043)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.51" spread="19.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 6 (n=1043)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.01" spread="17.911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 2 (n=1049)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.31" spread="18.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 4 (n=1049)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.24" spread="20.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 6 (n=1049)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.49" spread="21.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 2 (n=1077)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.18" spread="18.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 4 (n=1077)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.92" spread="17.615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 6 (n=1077)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.81" spread="20.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in participant serum CRP by the physician's expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in participant serum CRP by the physician's expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High disease activity - Month 2 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.35" spread="19.948"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 4 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.02" spread="23.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 6 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.41" spread="20.392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 2 (n=313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.74" spread="19.737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 4 (n=313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.72" spread="20.915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 6 (n=313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.97" spread="22.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 2 (n=1906)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.82" spread="19.413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 4 (n=1906)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.70" spread="19.519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 6 (n=1906)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.86" spread="20.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 2 (n=959)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.80" spread="13.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 4 (n=959)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.13" spread="17.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 6 (n=959)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.32" spread="17.589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in physician global assessment of disease activity was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in physician global assessment of disease activity was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low MTX Dose - Month 2 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.6" spread="19.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 4 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.1" spread="21.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 6 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.8" spread="22.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 2 (n=523)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.9" spread="21.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 4 (n=523)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.4" spread="21.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 6 (n=523)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.2" spread="22.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 2 (n=1987)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.1" spread="20.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 4 (n=1987)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.9" spread="21.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 6 (n=1987)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.3" spread="22.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the physician global assessment of disease by concomitant DMARD background treatment was evaluated at Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the physician global assessment of disease by concomitant DMARD background treatment was evaluated at Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DMARD Combination 1 - Month 2 (n=1674)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.7" spread="20.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 4 (n=1674)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.0" spread="21.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 6 (n=1674)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.5" spread="23.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 2 (n=432)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.5" spread="21.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 4 (n=432)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.5" spread="21.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 6 (n=432)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.5" spread="21.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 2 (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.9" spread="20.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 4 (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.8" spread="21.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 6 (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.1" spread="22.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 2 (n=149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.1" spread="20.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 -Month 4 (n=149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.5" spread="20.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 6 (n=149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.7" spread="22.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 2 (n=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.1" spread="21.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 4 (n=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.5" spread="21.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 6 (n=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.7" spread="22.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 2 (n=302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.4" spread="21.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 4 (n=302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.3" spread="22.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 6 (n=302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.3" spread="23.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the physician global assessment of disease activity by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the physician global assessment of disease activity by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did Not Receive Corticosteroids - Month 2 (n=1197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.6" spread="20.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 4 (n=1197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.3" spread="21.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 6 (n=1197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.9" spread="23.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 2 (n=2069)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.0" spread="21.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 4 (n=2069)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.3" spread="21.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 6 (n=2069)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.8" spread="22.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the physician global assessment of disease activity score by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the physician global assessment of disease activity score by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failed 1 DMARD - Month 2 (n=1124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.7" spread="20.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 4 (n=1124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.8" spread="22.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 6 (n=1124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.1" spread="23.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 2 (n=1171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.5" spread="21.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 4 (n=1171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.8" spread="20.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 6 (n=1171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.7" spread="21.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 2 (n=970)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.2" spread="19.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 4 (n=970)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.2" spread="21.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 6 (n=970)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.6" spread="23.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the physician global assessment of disease activity by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the physician global assessment of disease activity by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Duration &lt; 2 years - Month 2 (n=895)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.5" spread="21.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 4 (n=895)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.7" spread="22.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 6 (n=895)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.3" spread="23.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 2 (n=761)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.0" spread="20.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 4 (n=761)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.4" spread="21.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 6 (n=761)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.5" spread="22.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 2 (n=688)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.6" spread="2128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 4 (n=688)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.4" spread="21.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 6 (n=688)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.7" spread="22.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 2 (n=921)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.7" spread="19.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 4 (n=921)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.2" spread="21.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 6 (n=921)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.7" spread="22.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the physician global assessment of disease activity by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the physician global assessment of disease activity by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 2 (n=696)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.3" spread="19.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 4 (n=696)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.4" spread="20.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 6 (n=696)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.5" spread="20.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 2 (n=2560)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.4" spread="21.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 4 (n=2560)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.4" spread="21.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 6 (n=2560)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.9" spread="23.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the physician global assessment of disease activity by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the physician global assessment of disease activity by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RF &lt;=22 IU/mL - Month 2 (n=1023)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.9" spread="20.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 4 (n=1023)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.9" spread="21.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 6 (n=1023)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.2" spread="22.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 2 (n=1077)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.9" spread="20.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 4 (n=1077)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.4" spread="21.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 6 (n=1077)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.5" spread="22.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 2 (n=1120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.5" spread="20.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 4 (n=1120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.3" spread="21.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 6 (n=1120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.5" spread="22.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the physician global assessment of disease activity by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR or at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the physician global assessment of disease activity by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR or at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 2 (n=1035)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.6" spread="20.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 4 (n=1035)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.4" spread="22.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 6 (n=1035)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.6" spread="23.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 2 (n=1105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.6" spread="20.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 4 (n=1105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.0" spread="21.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 6 (n=1105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.7" spread="22.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 2 (n=1071)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.1" spread="20.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 4 (n=1071)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.2" spread="21.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 6 (n=1071)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.2" spread="21.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the physician global assessment of disease activity by participant baseline smoking status was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the physician global assessment of disease activity by participant baseline smoking status was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoker - Month 2 (n=1954)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.0" spread="20.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 4 (n=1954)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.9" spread="21.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 6 (n=1954)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.3" spread="22.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 2 (n=323)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.5" spread="19.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 4 (n=323)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.3" spread="21.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 6 (n=323)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.7" spread="21.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 2 (n=313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.3" spread="20.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 4 (n=313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.1" spread="21.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 6 (n=313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.1" spread="24.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 2 (n=222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.0" spread="19.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 4 (n=222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.0" spread="22.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 pack/day - Month 6 (n=222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.8" spread="24.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 2 (n=395)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.6" spread="20.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 4 (n=395)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.6" spread="22.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 6 (n=395)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.6" spread="23.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 2 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.7" spread="24.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 4 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.9" spread="22.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 6 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.2" spread="21.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 2 (n=422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.8" spread="20.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 4 (n=422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.8" spread="22.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 6 (n=422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.7" spread="24.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 2 (n=451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.2" spread="19.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 4 (n=451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.5" spread="20.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 6 (n=451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.8" spread="23.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 2 (n=417)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.7" spread="20.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 4 (n=417)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.3" spread="22.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 6 (n=417)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.6" spread="22.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the physician global assessment of disease activity by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the physician global assessment of disease activity by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 2 (n=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.0" spread="18.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 4 (n=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.9" spread="19.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 6 (n=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.6" spread="20.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 2 (n=3161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.6" spread="20.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 4 (n=3161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.1" spread="21.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 6 (n=3161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.3" spread="22.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the physician global assessment of disease activity by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] -100mm [worst]) with increasing scores indicating increased level of disease. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the physician global assessment of disease activity by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] -100mm [worst]) with increasing scores indicating increased level of disease. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=1.5 - Month 2 (n=1208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.4" spread="21.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 4 (n=1208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.7" spread="22.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 6 (n=1208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.2" spread="23.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 2 (n=1005)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.2" spread="20.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 4 (n=1005)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.3" spread="21.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 6 (n=1005)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.0" spread="22.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 2 (n=1049)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.6" spread="19.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 4 (n=1049)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.6" spread="21.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 6 (n=1049)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.8" spread="23.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the physician global assessment of disease activity by the treating physician level of experience was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the physician global assessment of disease activity by the treating physician level of experience was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=10 years - Month 2 (n=1305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.7" spread="21.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 4 (n=1305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.2" spread="21.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 6 (n=1305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.0" spread="23.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 2 (n=1101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.6" spread="20.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 4 (n=1101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.6" spread="21.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 6 (n=1101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.8" spread="22.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 2 (n=846)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.5" spread="20.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 4 (n=846)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.9" spread="21.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 6 (n=846)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.1" spread="22.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the physician global assessment of disease activity by physician experience level with biologics was evaluated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the physician global assessment of disease activity by physician experience level with biologics was evaluated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 to 6 years - Month 2 (n=1159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.5" spread="20.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 4 (n=1159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.5" spread="21.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 6 (n=1159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.3" spread="23.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 2 (n=1740)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.9" spread="20.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 4 (n=1740)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.2" spread="21.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 6 (n=1740)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.1" spread="22.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 2 (n=353)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.4" spread="19.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 4 (n=353)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.3" spread="21.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 6 (n=353)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.6" spread="22.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the physician global assessment of disease activity by the number of patients treated with biologics by the treating physician was evaluated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the physician global assessment of disease activity by the number of patients treated with biologics by the treating physician was evaluated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-17 patients in prior month - Month 2 (n=1053)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.1" spread="19.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 4 (n=1053)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.4" spread="20.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 6 (n=1053)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.3" spread="21.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 2 (n=1060)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.5" spread="21.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 4 (n=1060)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.7" spread="21.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 6 (n=1060)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.0" spread="23.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 2 (n=1095)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.0" spread="21.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 4 (n=1095)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.7" spread="22.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 6 (n=1095)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.0" spread="23.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the physician global assessment of disease activity by the baseline physician expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the physician global assessment of disease activity by the baseline physician expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm [best] - 100mm [worst]) with increasing scores indicating increased level of disease. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High disease activity - Month 2 (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.5" spread="18.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 4 (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.3" spread="24.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 6 (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.9" spread="28.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 2 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.1" spread="20.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 4 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.6" spread="22.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 6 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.4" spread="23.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 2 (n=1927)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.8" spread="20.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 4 (n=1927)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.6" spread="21.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 6 (n=1927)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.0" spread="22.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 2 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.0" spread="20.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 4 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.6" spread="21.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 6 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.1" spread="23.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-ESR Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the DAS28-ESR was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-ESR Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the DAS28-ESR was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low MTX Dose - Month 2 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.40" spread="1.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 4 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.97" spread="1.271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 6 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" spread="1.358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 2 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" spread="1.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 4 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" spread="1.252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 6 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.35" spread="1.400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 2 (n=1995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="1.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 4 (n=1995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="1.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 6 (n=1995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" spread="1.376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
        <description>The DAS28-ESR measures disease burden using patient global health (self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX+sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
          <description>The DAS28-ESR measures disease burden using patient global health (self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX+sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DMARD Combination 1 - Month 2 (n=1681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="1.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 4 (n=1681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.03" spread="1.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 6 (n=1681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.32" spread="1.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 2 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="1.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 4 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" spread="1.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 6 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.32" spread="1.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 2 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="1.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 4 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.85" spread="1.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 6 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.10" spread="1.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 2 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="1.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 -Month 4 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.12" spread="1.334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 6 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.46" spread="1.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 2 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="1.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 4 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.09" spread="1.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 6 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.18" spread="1.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 2 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.40" spread="1.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 4 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.90" spread="1.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 6 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.13" spread="1.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-ESR by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the DAS28-ESR by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt;3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-ESR by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the DAS28-ESR by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt;3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did Not Receive Corticosteroids - Month 2 (n=1202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="1.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 4 (n=1202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="1.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 6 (n=1202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.30" spread="1.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 2 (n=2078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="1.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 4 (n=2078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.95" spread="1.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 6 (n=2078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" spread="1.376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-ESR Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the DAS28-ESR score by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed on a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-ESR Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the DAS28-ESR score by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed on a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failed 1 DMARD - Month 2 (n=1129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="1.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 4 (n=1129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.05" spread="1.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 6 (n=1129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.32" spread="1.471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 2 (n=1176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="1.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 4 (n=1176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.93" spread="1.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 6 (n=1176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" spread="1.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 2 (n=974)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="1.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 4 (n=974)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="1.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 6 (n=974)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.20" spread="1.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-ESR Score by Duration of Disease at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the DAS28-ESR score by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed on a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt;5.1 = high disease activity, DAS28-ESR &lt;3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-ESR Score by Duration of Disease at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the DAS28-ESR score by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed on a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt;5.1 = high disease activity, DAS28-ESR &lt;3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Duration &lt; 2 years - Month 2 (n=899)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="1.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 4 (n=899)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.97" spread="1.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 6 (n=899)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.25" spread="1.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 2 (n=764)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" spread="1.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 4 (n=764)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.97" spread="1.214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 6 (n=764)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" spread="1.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 2 (n=692)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.40" spread="1.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 4 (n=692)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.97" spread="1.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 6 (n=692)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.25" spread="1.385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 2 (n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="1.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 4 (n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.97" spread="1.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 6 (n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.30" spread="1.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-ESR Score by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the DAS28-ESR score by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR with increasing scores indicating increased level of disease burden. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-ESR Score by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the DAS28-ESR score by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR with increasing scores indicating increased level of disease burden. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 2 (n=698)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.10" spread="1.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 4 (n=698)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" spread="1.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 6 (n=698)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.61" spread="1.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 2 (n=2572)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" spread="1.111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 4 (n=2572)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.12" spread="1.272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 6 (n=2572)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.45" spread="1.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-ESR Score by Baseline RF Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the DAS28-ESR by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. Increasing scores indicate increased burden of disease. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-ESR Score by Baseline RF Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the DAS28-ESR by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. Increasing scores indicate increased burden of disease. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RF &lt;=22 IU/mL - Month 2 (n=1026)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 4 (n=1026)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.90" spread="1.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 6 (n=1026)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.19" spread="1.427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 2 (n=1081)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="1.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 4 (n=1081)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.95" spread="1.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 6 (n=1081)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.21" spread="1.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 2 (n=1127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.49" spread="1.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 4 (n=1127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.06" spread="1.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 6 (n=1127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.38" spread="1.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-ESR Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the DAS28-ESR score by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. Increasing scores indicate increased burden of disease. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-ESR Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the DAS28-ESR score by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. Increasing scores indicate increased burden of disease. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 2 (n=1038)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="1.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 4 (n=1038)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.85" spread="1.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 6 (n=1038)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.17" spread="1.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 2 (n=1112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="1.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 4 (n=1112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" spread="1.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 6 (n=1112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.27" spread="1.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 2 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="1.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 4 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" spread="1.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 6 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.35" spread="1.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6</title>
        <description>The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6</title>
          <description>The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoker - Month 2 (n=1963)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="1.111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 4 (n=1963)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" spread="1.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 6 (n=1963)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.36" spread="1.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 2 (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="1.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 4 (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.88" spread="1.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 6 (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" spread="1.355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 2 (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 4 (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.99" spread="1.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 6 (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="1.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 2 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" spread="1.111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 4 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.87" spread="1.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 pack/day - Month 6 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.17" spread="1.522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 2 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="1.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 4 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.76" spread="1.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 6 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.90" spread="1.376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 2 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="1.369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 4 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="1.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 6 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.77" spread="1.521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 2 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="1.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 4 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" spread="1.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 6 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" spread="1.463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 2 (n=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="1.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 4 (n=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" spread="1.247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 6 (n=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.16" spread="1.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 2 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="1.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 4 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.69" spread="1.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 6 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.93" spread="1.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-ESR Score by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the DAS28-ESR score by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-ESR Score by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the DAS28-ESR score by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 2 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="0.881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 4 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.87" spread="1.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 6 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" spread="1.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 2 (n=3174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="1.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 4 (n=3174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.97" spread="1.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 6 (n=3174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.27" spread="1.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-ESR Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the DAS28-ESR score by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-ESR Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the DAS28-ESR score by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=1.5 - Month 2 (n=1212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="1.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 4 (n=1212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.11" spread="1.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 6 (n=1212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.43" spread="1.377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 2 (n=1009)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.40" spread="1.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 4 (n=1009)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" spread="1.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 6 (n=1009)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="1.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 2 (n=1054)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="1.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 4 (n=1054)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" spread="1.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 6 (n=1054)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" spread="1.344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level at Month 2, Month 4, and Month 6</title>
        <description>The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level at Month 2, Month 4, and Month 6</title>
          <description>The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=10 years - Month 2 (n=1305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="1.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 4 (n=1305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.93" spread="1.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 6 (n=1305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.20" spread="1.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 2 (n=1105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="1.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 4 (n=1105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.03" spread="1.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 6 (n=1105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.38" spread="1.423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 2 (n=850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="1.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 4 (n=850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.95" spread="1.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 6 (n=850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.22" spread="1.359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 to 6 years - Month 2 (n=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="1.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 4 (n=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" spread="1.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 6 (n=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.22" spread="1.359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 2 (n=1745)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="1.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 4 (n=1745)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.97" spread="1.293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 6 (n=1745)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="1.385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 2 (n=355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="1.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 4 (n=355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.05" spread="1.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 6 (n=355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.33" spread="1.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-ESR Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-ESR Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-17 patients in prior month - Month 2 (n=1056)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 4 (n=1056)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.89" spread="1.154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 6 (n=1056)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" spread="1.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 2 (n=1061)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="1.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 4 (n=1061)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" spread="1.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 6 (n=1061)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" spread="1.392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 2 (n=1097)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="1.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 4 (n=1097)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="1.350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 6 (n=1097)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.27" spread="1.449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 = low disease activity, and DAS28-ESR &lt;2.6 = remission. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High disease activity - Month 2 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.84" spread="1.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 4 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="1.359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 6 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.54" spread="1.638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 2 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="1.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 4 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.72" spread="1.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 6 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.06" spread="1.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 2 (n=1932)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="1.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 4 (n=1932)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.95" spread="1.252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 6 (n=1932)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" spread="1.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 2 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.54" spread="1.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 4 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.09" spread="1.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 6 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.37" spread="1.400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-CRP Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the DAS28-CRP was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-CRP Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the DAS28-CRP was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low MTX Dose - Month 2 (n=138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 4 (n=138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.87" spread="1.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 6 (n=138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.18" spread="1.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 2 (n=519)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="1.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 4 (n=519)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" spread="1.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 6 (n=519)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" spread="1.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 2 (n=1967)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 4 (n=1967)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.87" spread="1.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 6 (n=1967)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.16" spread="1.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
        <description>The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts &amp; swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP &gt;5.1 =high disease activity, DAS28-CRP &lt;3.2=low disease activity, and DAS28-CRP &lt;2.6=remission. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 =leflunomide.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
          <description>The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts &amp; swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP &gt;5.1 =high disease activity, DAS28-CRP &lt;3.2=low disease activity, and DAS28-CRP &lt;2.6=remission. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 =leflunomide.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DMARD Combination 1 - Month 2 (n=1662)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="1.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 4 (n=1662)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.90" spread="1.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 6 (n=1662)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.18" spread="1.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 2 (n=424)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="1.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 4 (n=424)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" spread="1.252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 6 (n=424)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.21" spread="1.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 2 (n=211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="1.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 4 (n=211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.76" spread="1.203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 6 (n=211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" spread="1.308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 2 (n=147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="1.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 -Month 4 (n=147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="1.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 6 (n=147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.33" spread="1.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 2 (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="1.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 4 (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.95" spread="1.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 6 (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.10" spread="1.303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 2 (n=301)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="1.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 4 (n=301)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" spread="1.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 6 (n=301)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.06" spread="1.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-CRP by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the DAS28-CRP by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-CRP by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the DAS28-CRP by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did Not Receive Corticosteroids - Month 2 (n=1187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 4 (n=1187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" spread="1.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 6 (n=1187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.16" spread="1.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 2 (n=2048)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="1.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 4 (n=2048)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" spread="1.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 6 (n=2048)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.14" spread="1.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-CRP Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the DAS28-CRP score by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-CRP Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the DAS28-CRP score by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failed 1 DMARD - Month 2 (n=1118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="1.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 4 (n=1118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.91" spread="1.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 6 (n=1118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.19" spread="1.366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 2 (n=1158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="1.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 4 (n=1158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" spread="1.186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 6 (n=1158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.13" spread="1.271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 2 (n=958)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="0.993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 4 (n=958)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.84" spread="1.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 6 (n=958)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.12" spread="1.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-CRP Score by Duration of Disease at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the DAS28-CRP score by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-CRP Score by Duration of Disease at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the DAS28-CRP score by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Duration &lt; 2 years - Month 2 (n=885)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="1.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 4 (n=885)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.82" spread="1.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 6 (n=885)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.10" spread="1.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 2 (n=756)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="1.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 4 (n=756)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.90" spread="1.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 6 (n=756)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.16" spread="1.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 2 (n=681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="1.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 4 (n=681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.87" spread="1.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 6 (n=681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.12" spread="1.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 2 (n=912)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="1.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 4 (n=912)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.87" spread="1.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 6 (n=912)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.20" spread="1.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-CRP Score by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the DAS28-CRP score by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP with increasing scores indicating increased burden of disease. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-CRP &gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-CRP Score by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the DAS28-CRP score by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP with increasing scores indicating increased burden of disease. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-CRP &gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 2 (n=687)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.06" spread="0.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 4 (n=687)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="1.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 6 (n=687)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" spread="1.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 2 (n=2538)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" spread="1.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 4 (n=2538)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="1.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 6 (n=2538)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.31" spread="1.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-CRP Score by Baseline RF Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the DAS28-CRP by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-CRP Score by Baseline RF Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the DAS28-CRP by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RF &lt;=22 IU/mL - Month 2 (n=1025)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" spread="1.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 4 (n=1025)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" spread="1.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 6 (n=1025)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.02" spread="1.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 2 (n=1079)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 4 (n=1079)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.85" spread="1.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 6 (n=1079)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.12" spread="1.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 2 (n=1125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="1.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 4 (n=1125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.98" spread="1.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 6 (n=1125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" spread="1.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-CRP Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the DAS28-CRP score by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-CRP Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the DAS28-CRP score by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 2 (n=1027)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="1.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 4 (n=1027)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.73" spread="1.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 6 (n=1027)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.02" spread="1.285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 2 (n=1101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="1.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 4 (n=1101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="1.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 6 (n=1101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.16" spread="1.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 2 (n=1070)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" spread="1.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 4 (n=1070)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="1.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 6 (n=1070)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" spread="1.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6</title>
        <description>The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6</title>
          <description>The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoker - Month 2 (n=1941)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="1.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 4 (n=1941)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" spread="1.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 6 (n=1941)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" spread="1.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 2 (n=318)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="1.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 4 (n=318)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.74" spread="1.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 6 (n=318)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.11" spread="1.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 2 (n=312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="1.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 4 (n=312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.88" spread="1.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 6 (n=312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.15" spread="1.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 2 (n=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="1.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 4 (n=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.76" spread="1.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 pack/day - Month 6 (n=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" spread="1.364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 2 (n=388)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="0.984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 4 (n=388)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="1.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 6 (n=388)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.77" spread="1.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 2 (n=58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="1.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 4 (n=58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" spread="1.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 6 (n=58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="1.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 2 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 4 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.82" spread="1.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 6 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.12" spread="1.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 2 (n=450)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="1.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 4 (n=450)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" spread="1.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 6 (n=450)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.03" spread="1.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 2 (n=405)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="0.989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 4 (n=405)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="1.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 6 (n=405)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.81" spread="1.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-CRP Score by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the DAS28-CRP score by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-CRP Score by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the DAS28-CRP score by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 2 (n=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="0.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 4 (n=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" spread="0.982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 6 (n=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.81" spread="1.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 2 (n=3130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="1.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 4 (n=3130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.87" spread="1.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 6 (n=3130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.16" spread="1.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-CRP Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the DAS28-CRP score by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-CRP Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the DAS28-CRP score by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=1.5 - Month 2 (n=1201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="1.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 4 (n=1201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.97" spread="1.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 6 (n=1201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.31" spread="1.285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 2 (n=995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="1.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 4 (n=995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="1.212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 6 (n=995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.16" spread="1.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 2 (n=1034)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="1.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 4 (n=1034)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.67" spread="1.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 6 (n=1034)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" spread="1.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level at Month 2, Month 4, and Month 6</title>
        <description>The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level at Month 2, Month 4, and Month 6</title>
          <description>The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=10 years - Month 2 (n=1284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="1.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 4 (n=1284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" spread="1.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 6 (n=1284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.12" spread="1.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 2 (n=1094)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="1.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 4 (n=1094)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.93" spread="1.242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 6 (n=1094)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" spread="1.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 2 (n=837)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="1.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 4 (n=837)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" spread="1.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 6 (n=837)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.09" spread="1.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 to 6 years - Month 2 (n=1147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="1.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 4 (n=1147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" spread="1.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 6 (n=1147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.16" spread="1.281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 2 (n=1717)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="1.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 4 (n=1717)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.87" spread="1.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 6 (n=1717)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.14" spread="1.292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 2 (n=351)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.40" spread="1.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 4 (n=351)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.93" spread="1.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 6 (n=351)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.16" spread="1.337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-CRP Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-CRP Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-17 patients in prior month - Month 2 (n=1043)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="1.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 4 (n=1043)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.81" spread="1.111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 6 (n=1043)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.21" spread="1.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 2 (n=1049)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="1.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 4 (n=1049)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.88" spread="1.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 6 (n=1049)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.13" spread="1.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 2 (n=1077)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="1.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 4 (n=1077)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.90" spread="1.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 6 (n=1077)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.11" spread="1.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DAS28-CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DAS28-CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP&gt; 5.1 = high disease activity, DAS28-CRP &lt; 3.2 = low disease activity, and DAS28-CRP &lt;2.6 = remission. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High disease activity - Month 2 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.68" spread="1.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 4 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.10" spread="1.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 6 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.57" spread="1.485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 2 (n=313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="0.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 4 (n=313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.67" spread="1.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 6 (n=313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.96" spread="1.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 2 (n=1906)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="1.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 4 (n=1906)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.85" spread="1.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 6 (n=1906)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.14" spread="1.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 2 (n=959)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="1.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 4 (n=959)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" spread="1.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 6 (n=959)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.20" spread="1.271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Simplified Disease Activity Index (SDAI) Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the SDAI was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28‚Äêjoint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10cm [worst]) and level of C-reactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Simplified Disease Activity Index (SDAI) Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the SDAI was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28‚Äêjoint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10cm [worst]) and level of C-reactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low MTX Dose - Month 2 (n=138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.55" spread="11.605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 4 (n=138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.69" spread="13.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 6 (n=138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.81" spread="14.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 2 (n=516)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.74" spread="11.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 4 (n=516)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.38" spread="12.872"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 6 (n=516)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.01" spread="13.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 2 (n=1959)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.99" spread="11.920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 4 (n=1959)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.52" spread="13.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 6 (n=1959)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.00" spread="13.743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
        <description>The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
          <description>The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DMARD Combination 1 - Month 2 (n=1655)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.22" spread="11.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 4 (n=1655)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.59" spread="12.977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 6 (n=1655)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.07" spread="13.766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 2 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.16" spread="12.811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 4 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.02" spread="13.780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 6 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.31" spread="13.540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 2 (n=210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.64" spread="13.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 4 (n=210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.84" spread="13.763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 6 (n=210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.41" spread="14.685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 2 (n=146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.86" spread="11.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 -Month 4 (n=146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.52" spread="12.601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 6 (n=146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.45" spread="14.879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 2 (n=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.63" spread="11.838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 4 (n=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.71" spread="11.925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 6 (n=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.67" spread="13.876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 2 (n=300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.11" spread="11.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 4 (n=300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.70" spread="12.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 6 (n=300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.41" spread="13.670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SDAI by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the SDAI by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28‚Äêjoint assessment), patient and physician global assessment of disease activity (VAS 0 cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SDAI by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the SDAI by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28‚Äêjoint assessment), patient and physician global assessment of disease activity (VAS 0 cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did Not Receive Corticosteroids - Month 2 (n=1182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.86" spread="11.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 4 (n=1182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.20" spread="12.452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 6 (n=1182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.50" spread="13.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 2 (n=2039)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.12" spread="12.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 4 (n=2039)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.54" spread="13.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 6 (n=2039)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.12" spread="13.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SDAI by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the SDAI by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28‚Äêjoint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SDAI by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the SDAI by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28‚Äêjoint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failed 1 DMARD - Month 2 (n=1113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.69" spread="11.955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 4 (n=1113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.82" spread="13.873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 6 (n=1113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.31" spread="14.472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 2 (n=1153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.97" spread="11.902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 4 (n=1153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.26" spread="12.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 6 (n=1153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.74" spread="13.451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 2 (n=954)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.33" spread="11.303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 4 (n=954)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.12" spread="12.421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 6 (n=954)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.60" spread="13.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SDAI by Duration of Disease at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the SDAI by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28‚Äêjoint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SDAI by Duration of Disease at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the SDAI by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28‚Äêjoint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Duration &lt; 2 years - Month 2 (n=881)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.62" spread="12.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 4 (n=881)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.74" spread="13.904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 6 (n=881)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.04" spread="14.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 2 (n=753)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.37" spread="11.745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 4 (n=753)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.84" spread="12.672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 6 (n=753)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.12" spread="13.619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 2 (n=677)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.75" spread="11.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 4 (n=677)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.50" spread="12.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 6 (n=677)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.63" spread="13.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 2 (n=909)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.35" spread="11.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 4 (n=909)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.65" spread="12.804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 6 (n=909)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.71" spread="13.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SDAI by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the SDAI by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28‚Äêjoint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease with increasing scores indicating increased burden of disease. DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SDAI by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the SDAI by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28‚Äêjoint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease with increasing scores indicating increased burden of disease. DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 2 (n=685)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.34" spread="8.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 4 (n=685)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.20" spread="8.638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 6 (n=685)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.42" spread="8.997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 2 (n=2526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.61" spread="12.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 4 (n=2526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.66" spread="13.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 6 (n=2526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.48" spread="13.745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SDAI by Baseline RF Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the SDAI by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SDAI by Baseline RF Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the SDAI by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RF &lt;=22 IU/mL - Month 2 (n=1022)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.31" spread="11.369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 4 (n=1022)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.68" spread="12.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 6 (n=1022)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.03" spread="13.335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 2 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.73" spread="11.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 4 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.89" spread="12.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 6 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.09" spread="13.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 2 (n=1118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.88" spread="12.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 4 (n=1118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.53" spread="13.618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 6 (n=1118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.38" spread="14.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SDAI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the SDAI by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SDAI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the SDAI by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 2 (n=1024)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.40" spread="11.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 4 (n=1024)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.92" spread="12.860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 6 (n=1024)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.41" spread="13.526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 2 (n=1094)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.39" spread="11.601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 4 (n=1094)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.01" spread="12.787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 6 (n=1094)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.89" spread="13.718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 2 (n=1066)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.23" spread="12.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 4 (n=1066)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.23" spread="13.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 6 (n=1066)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.38" spread="14.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6</title>
        <description>The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6</title>
          <description>The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoker - Month 2 (n=1932)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.64" spread="11.959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 4 (n=1932)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.45" spread="13.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 6 (n=1932)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.25" spread="13.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 2 (n=317)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.10" spread="11.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 4 (n=317)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.34" spread="13.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 6 (n=317)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.54" spread="14.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 2 (n=311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.16" spread="11.477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 4 (n=311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.81" spread="12.777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 6 (n=311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.09" spread="13.648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 2 (n=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.29" spread="11.523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 4 (n=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.75" spread="12.965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 pack/day - Month 6 (n=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.63" spread="13.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 2 (n=386)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.85" spread="10.766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 4 (n=386)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.31" spread="12.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 6 (n=386)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.53" spread="13.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 2 (n=58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.23" spread="14.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 4 (n=58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.48" spread="13.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 6 (n=58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.91" spread="14.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 2 (n=417)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.03" spread="11.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 4 (n=417)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.22" spread="13.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 6 (n=417)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.30" spread="14.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 2 (n=447)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.06" spread="11.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 4 (n=447)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.43" spread="12.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 6 (n=447)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.97" spread="13.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 2 (n=404)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.27" spread="10.943"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 4 (n=404)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.00" spread="12.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 6 (n=404)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.27" spread="13.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SDAI by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the SDAI by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SDAI by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the SDAI by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 2 (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.10" spread="9.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 4 (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.08" spread="10.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 6 (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.50" spread="11.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible- Month 2 (n=3117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.12" spread="11.823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 4 (n=3117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.52" spread="13.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 6 (n=3117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.07" spread="13.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SDAI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the SDAI by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SDAI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the SDAI by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=1.5 - Month 2 (n=1197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.51" spread="12.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 4 (n=1197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.74" spread="13.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 6 (n=1197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.42" spread="13.894"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 2 (n=991)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.24" spread="11.600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 4 (n=991)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.04" spread="13.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 6 (n=991)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.20" spread="13.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 2 (n=1029)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.09" spread="11.276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 4 (n=1029)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.24" spread="12.411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 6 (n=1029)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.76" spread="13.431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SDAI by Physician Experience Level at Month 2, Month 4, and Month 6</title>
        <description>The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SDAI by Physician Experience Level at Month 2, Month 4, and Month 6</title>
          <description>The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=10 years - Month 2 (n=1284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.49" spread="11.734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 4 (n=1284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.20" spread="12.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 6 (n=1284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.60" spread="13.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 2 (n=1090)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.62" spread="11.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 4 (n=1090)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.95" spread="13.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 6 (n=1090)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.71" spread="13.926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 2 (n=833)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.10" spread="11.571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 4 (n=833)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.13" spread="12.810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 6 (n=833)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.32" spread="13.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SDAI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SDAI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 to 6 years - Month 2 (n=1146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.71" spread="11.851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 4 (n=1146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.41" spread="13.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 6 (n=1146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.43" spread="13.784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 2 (n=1712)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.25" spread="11.694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 4 (n=1712)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.50" spread="13.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 6 (n=1712)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.75" spread="13.831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 2 (n=349)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.99" spread="11.616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 4 (n=349)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.17" spread="12.644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 6 (n=349)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.93" spread="13.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SDAI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SDAI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-17 patients in prior month - Month 2 (n=1040)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.80" spread="11.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 4 (n=1040)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.65" spread="12.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 6 (n=1040)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.32" spread="13.447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 2 (n=1048)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.32" spread="11.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 4 (n=1048)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.51" spread="13.421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 6 (n=1048)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.65" spread="13.603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 2 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.05" spread="11.797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 4 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.19" spread="13.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 6 (n=1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.88" spread="14.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SDAI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SDAI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm [best] ‚Äì 10 cm [worst]) and level of C‚Äêreactive protein (mg/dL, normal &lt;1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High disease activity - Month 2 (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.26" spread="11.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 4 (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.66" spread="11.626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 6 (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.55" spread="13.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 2 (n=313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.78" spread="11.904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 4 (n=313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.39" spread="12.757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 6 (n=313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.22" spread="14.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 2 (n=1901)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.93" spread="11.812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 4 (n=1901)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.65" spread="13.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 6 (n=1901)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.33" spread="13.892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 2 (n=959)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.16" spread="11.560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 4 (n=959)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.91" spread="12.675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 6 (n=959)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.79" spread="13.418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved DAS28-ESR EULAR Response</title>
        <description>EULAR response was assessed at the end of Month 2, Month 4, and Month 6 by the Disease Activity Score using the 28 tender and swollen joint count calculated with erythrocyte sedimentation rate values (DAS28-ESR). A good response would was defined as a decrease &gt;1.2 units and a final DAS28-ESR &lt; 3.2 units, while a moderate response was defined as a decrease &gt; 1.2 units and final DAS28-ESR &gt;= 3.2 units, OR a decrease of 0.6 to 1.2.</description>
        <time_frame>Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>In Part 1 of the trial, participants received subcutaneous golimumab 50 mg once monthly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved DAS28-ESR EULAR Response</title>
          <description>EULAR response was assessed at the end of Month 2, Month 4, and Month 6 by the Disease Activity Score using the 28 tender and swollen joint count calculated with erythrocyte sedimentation rate values (DAS28-ESR). A good response would was defined as a decrease &gt;1.2 units and a final DAS28-ESR &lt; 3.2 units, while a moderate response was defined as a decrease &gt; 1.2 units and final DAS28-ESR &gt;= 3.2 units, OR a decrease of 0.6 to 1.2.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved DAS28-CRP EULAR Response</title>
        <description>DAS28-CRP EULAR response is defined as a good or moderate response that results in a DAS28-CRP &gt;=0.6.</description>
        <time_frame>Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>In Part 1 of the trial, participants received subcutaneous golimumab 50 mg once monthly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved DAS28-CRP EULAR Response</title>
          <description>DAS28-CRP EULAR response is defined as a good or moderate response that results in a DAS28-CRP &gt;=0.6.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6</title>
        <description>The number of participants achieving low disease activity or remission was calculated by the DAS28-ESR, DAS28-CRP, and SDAI at study Month 2, Month 4, and Month 6. Low disease activity by DAS28-ESR was defined as &gt;= 2.6 to 3.2, and remission was defined as a DAS28-ESR &lt;2.6. Low disease activity by DAS28-CRP was defined as DAS28-CRP &gt;=2.6 to 3.2, and remission was defined as DAS28-CRP &gt;2.6. Low disease activity by SDAI was defined as SDAI &gt;5.0 to &lt;=20, and remission was defined as SDAI &lt;=5.0.</description>
        <time_frame>Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6</title>
          <description>The number of participants achieving low disease activity or remission was calculated by the DAS28-ESR, DAS28-CRP, and SDAI at study Month 2, Month 4, and Month 6. Low disease activity by DAS28-ESR was defined as &gt;= 2.6 to 3.2, and remission was defined as a DAS28-ESR &lt;2.6. Low disease activity by DAS28-CRP was defined as DAS28-CRP &gt;=2.6 to 3.2, and remission was defined as DAS28-CRP &gt;2.6. Low disease activity by SDAI was defined as SDAI &gt;5.0 to &lt;=20, and remission was defined as SDAI &lt;=5.0.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Disease Activity by DAS28-ESR - Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity by DAS28-ESR - Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity by DAS28-ESR - Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity by DAS28-CRP - Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity by DAS28-CRP - Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity by DAS28-CRP - Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity by SDAI - Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity by SDAI - Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity by SDAI - Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission by DAS28-ESR - Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission by DAS28-ESR - Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission by DAS28-ESR - Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission by DAS28-CRP - Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission by DAS28-CRP - Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission by DAS28-CRP - Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission by SDAI - Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission by SDAI - Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission by SDAI - Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ-DI) by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline the disability index of the HAQ was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst)with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ-DI) by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline the disability index of the HAQ was calculated by concomitant MTX dose (low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and high &gt;=15 mg/week) at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst)with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low MTX Dose - Month 2 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 4 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 6 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 2 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 4 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 6 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 2 (n=1993)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 4 (n=1993)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 6 (n=1993)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="0.649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
        <description>The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
          <description>The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DMARD Combination 1 - Month 2 (n=1679)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 4 (n=1679)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 6 (n=1679)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="0.651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 2 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 4 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 6 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="0.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 2 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 4 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 6 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 2 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 -Month 4 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 6 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 2 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 4 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="0.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 6 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 2 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 4 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 6 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in HAQ-DI by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the HAQ-DI by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in HAQ-DI by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the HAQ-DI by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did Not Receive Corticosteroids - Month 2 (n=1201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 4 (n=1201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 6 (n=1201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 2 (n=2076)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 4 (n=2076)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 6 (n=2076)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in HAQ-DI by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the HAQ-DI by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in HAQ-DI by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the HAQ-DI by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failed 1 DMARD - Month 2 (n=1128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 4 (n=1128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 6 (n=1128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 2 (n=1175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 4 (n=1175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 6 (n=1175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 2 (n=973)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 4 (n=973)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 6 (n=973)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in HAQ-DI by Duration of Disease at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the HAQ-DI by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in HAQ-DI by Duration of Disease at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the HAQ-DI by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Duration &lt; 2 years - Month 2 (n=897)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 4 (n=897)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 6 (n=897)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 2 (n=763)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 4 (n=763)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 6 (n=763)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="0.662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 2 (n=692)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 4 (n=692)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 6 (n=692)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 2 (n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 4 (n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 6 (n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in HAQ-DI by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the HAQ-DI by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in HAQ-DI by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the HAQ-DI by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 2 (n=697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 4 (n=697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 6 (n=697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 2 (n=2570)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 4 (n=2570)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 6 (n=2570)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in HAQ-DI by Baseline RF Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the HAQ-DI by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in HAQ-DI by Baseline RF Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the HAQ-DI by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RF &lt;=22 IU/mL - Month 2 (n=1025)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 4 (n=1025)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 6 (n=1025)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 2 (n=1080)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 4 (n=1080)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 6 (n=1080)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 2 (n=1126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 4 (n=1126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 6 (n=1126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in HAQ-DI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the HAQ-DI by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in HAQ-DI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the HAQ-DI by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 2 (n=1036)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 4 (n=1036)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 6 (n=1036)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 2 (n=1112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 4 (n=1112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 6 (n=1112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 2 (n=1074)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 4 (n=1074)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 6 (n=1074)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6</title>
        <description>The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6</title>
          <description>The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoker - Month 2 (n=1960)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 4 (n=1960)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 6 (n=1960)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 2 (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 4 (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 6 (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 2 (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 4 (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 6 (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 2 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 4 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 pack/day - Month 6 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 2 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 4 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 6 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 2 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 4 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 6 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 2 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 4 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 6 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 2 (n=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 4 (n=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 6 (n=454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 2 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 4 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 6 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in HAQ-DI by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the HAQ-DI by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in HAQ-DI by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the HAQ-DI by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 2 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 4 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 6 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible- Month 2 (n=3171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 4 (n=3171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EligAnti-TNF treatment Eligible - Month 6 (n=3171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="0.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in HAQ-DI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the HAQ-DI by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in HAQ-DI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the HAQ-DI by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=1.5 - Month 2 (n=1211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 4 (n=1211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 6 (n=1211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="0.691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 2 (n=1009)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 4 (n=1009)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 6 (n=1009)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 2 (n=1053)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 4 (n=1053)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 6 (n=1053)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in HAQ-DI by Physician Experience Level at Month 2, Month 4, and Month 6</title>
        <description>The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in HAQ-DI by Physician Experience Level at Month 2, Month 4, and Month 6</title>
          <description>The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=10 years - Month 2 (n=1304)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 4 (n=1304)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 6 (n=1304)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 2 (n=1104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 4 (n=1104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 6 (n=1104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 2 (n=850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 4 (n=850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 6 (n=850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in HAQ-DI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in HAQ-DI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 to 6 years - Month 2 (n=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 4 (n=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 6 (n=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 2 (n=1744)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 4 (n=1744)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 6 (n=1744)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 2 (n=354)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 4 (n=354)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 6 (n=354)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in HAQ-DI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a scores ranging from 0 (best) to 3 (best) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in HAQ-DI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a scores ranging from 0 (best) to 3 (best) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-17 patients in prior month - Month 2 (n=1055)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 4 (n=1055)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 6 (n=1055)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 2 (n=1060)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 4 (n=1060)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 6 (n=1060)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 2 (n=1097)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 4 (n=1097)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 6 (n=1097)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in HAQ-DI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in HAQ-DI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High disease activity - Month 2 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 4 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 6 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 2 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 4 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 6 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 2 (n=1930)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 4 (n=1930)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 6 (n=1930)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 2 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 4 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 6 (n=966)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved Minimal or Absence of Functional Impairment</title>
        <description>The number of participants that achieved minimal or absence of functional impairment as assessed by the HAQ at study Month 2, Month 4, and Month 6 was calculated. Minimal or absence of functional impairment was defined as a HAQ score of &lt;=0.5. The HAQ evaluates participants on a scale of 0 to 3, with 0=with no difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do.</description>
        <time_frame>Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>In Part 1 of the trial, participants received subcutaneous golimumab 50 mg once monthly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved Minimal or Absence of Functional Impairment</title>
          <description>The number of participants that achieved minimal or absence of functional impairment as assessed by the HAQ at study Month 2, Month 4, and Month 6 was calculated. Minimal or absence of functional impairment was defined as a HAQ score of &lt;=0.5. The HAQ evaluates participants on a scale of 0 to 3, with 0=with no difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the EuroQOL (EQ-5D) Quality-of-Life Questionnaire by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
        <description>Concomitant MTX dose was defined as low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and and high &gt;=15 mg/week. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the EuroQOL (EQ-5D) Quality-of-Life Questionnaire by Concomitant MTX Dose at Month 2, Month 4, and Month 6</title>
          <description>Concomitant MTX dose was defined as low &lt; 10mg/wk, medium &gt;= 10 to &lt; 15 mg/week, and and high &gt;=15 mg/week. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low MTX Dose - Month 2 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 4 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low MTX Dose - Month 6 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 2 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 4 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium MTX Dose - Month 6 (n=526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 2 (n=1985)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 4 (n=1985)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High MTX Dose - Month 6 (n=1985)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
        <description>The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. DMARD Combination 1=MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2=MTX + leflunomide; Combination 3=MTX +sulfasalazine; Combination 4=MTX + hydrochloroquine, chloroquine, chloroquine phosphate+sulfasalazine; Combination 5=leflunomide.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6</title>
          <description>The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. DMARD Combination 1=MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2=MTX + leflunomide; Combination 3=MTX +sulfasalazine; Combination 4=MTX + hydrochloroquine, chloroquine, chloroquine phosphate+sulfasalazine; Combination 5=leflunomide.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DMARD Combination 1 - Month 2 (n=1672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 4 (n=1672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 1 - Month 6 (n=1672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 2 (n=432)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 4 (n=432)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 2 - Month 6 (n=432)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 2 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 4 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 3 - Month 6 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 2 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 -Month 4 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 4 - Month 6 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 2 (n=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 4 (n=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 5 - Month 6 (n=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 2 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 4 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMARD Combination 6 - Month 6 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread=".341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EQ-5D by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the EQ-5D by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EQ-5D by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the EQ-5D by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did Not Receive Corticosteroids - Month 2 (n=1199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 4 (n=1199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Receive Corticosteroids - Month 6 (n=1199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 2 (n=2069)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 4 (n=2069)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received Corticosteroids - Month 6 (n=2069)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EQ-5D by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the EQ-5D by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EQ-5D by the Number of DMARD Failures at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the EQ-5D by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failed 1 DMARD - Month 2 (n=1124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 4 (n=1124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 1 DMARD - Month 6 (n=1124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 2 (n=1173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 4 (n=1173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed 2 DMARDs - Month 6 (n=1173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 2 (n=970)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 4 (n=970)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed &gt;=3 DMARDs - Month 6 (n=970)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EQ-5D by Duration of Disease at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the EQ-5D by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EQ-5D by Duration of Disease at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the EQ-5D by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Duration &lt; 2 years - Month 2 (n=893)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 4 (n=893)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &lt; 2 years - Month 6 (n=893)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 2 (n=760)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 4 (n=760)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 2 to &lt;5 years - Month 6 (n=760)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 2 (n=691)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 4 (n=691)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration 5 to 10 years - Month 6 (n=691)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 2 (n=923)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 4 (n=923)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration &gt; 10 years - Month 6 (n=923)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EQ-5D by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the EQ-5D by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EQ-5D by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the EQ-5D by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. DAS28-ESR &gt; 5.1 = high disease activity, DAS28-ESR &lt; 3.2 to &lt; =5.1 = low disease activity, and DAS28-ESR &lt;2.6 = remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 2 (n=695)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 4 (n=695)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 3.2 to &lt;=5.1 - Month 6 (n=695)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 2 (n=2563)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 4 (n=2563)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt; 5.1 - Month 6 (n=2563)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EQ-5D by Baseline RF Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the EQ-5D by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EQ-5D by Baseline RF Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the EQ-5D by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RF &lt;=22 IU/mL - Month 2 (n=1020)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 4 (n=1020)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &lt;=22 IU/mL - Month 6 (n=1020)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 2 (n=1079)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 4 (n=1079)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;22 to &lt;=146 IU/mL - Month 6 (n=1079)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 2 (n=1123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 4 (n=1123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF &gt;146 IU/mL - Month 6 (n=1123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EQ-5D by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the EQ-5D by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EQ-5D by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the EQ-5D by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 2 (n=1033)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 4 (n=1033)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;=40 U/mL - Month 6 (n=1033)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 2 (n=1109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 4 (n=1109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;40 to &lt;=380 U/mL - Month 6 (n=1109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 2 (n=1071)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 4 (n=1071)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;380 U/mL - Month 6 (n=1071)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6</title>
        <description>The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6</title>
          <description>The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoker - Month 2 (n=1957)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 4 (n=1957)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker - Month 6 (n=1957)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 2 (n=322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 4 (n=322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &gt;=20 years - Month 6 (n=322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 2 (n=312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 4 (n=312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking history &lt;20 years - Month 6 (n=312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 2 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 packs/day - Month 4 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &lt;0.5 pack/day - Month 6 (n=223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 2 (n=395)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 4 (n=395)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes 0.5-1 pack/day - Month 6 (n=395)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 2 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 4 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes &gt;1 packs/day - Month 6 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 2 (n=421)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 4 (n=421)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &lt;7.5 - Month 6 (n=421)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 2 (n=453)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 4 (n=453)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years 7.5 to 20.5 - Month 6 (n=453)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.335" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 2 (n=415)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 4 (n=415)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pack years &gt;20.5 - Month 6 (n=415)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EQ-5D by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the EQ-5D by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EQ-5D by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the EQ-5D by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 2 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 4 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Ineligible - Month 6 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 2 (n=3162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 4 (n=3162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TNF treatment Eligible - Month 6 (n=3162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EQ-5D by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The mean change from baseline in the EQ-5D by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EQ-5D by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The mean change from baseline in the EQ-5D by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: &lt;=1.5, &gt;1.5 to &lt;1.86, and &gt;=1.86.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=1.5 - Month 2 (n=1208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 4 (n=1208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=1.5 - Month 6 (n=1208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 2 (n=1006)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 4 (n=1006)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 to 1.86 - Month 6 (n=1006)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 2 (n=1050)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 4 (n=1050)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.86 - Month 6 (n=1050)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EQ-5D by Physician Experience Level at Month 2, Month 4, and Month 6</title>
        <description>The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EQ-5D by Physician Experience Level at Month 2, Month 4, and Month 6</title>
          <description>The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=10 years - Month 2 (n=1300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 4 (n=1300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=10 years - Month 6 (n=1300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 2 (n=1103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 4 (n=1103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 20 years - Month 6 (n=1103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 2 (n=847)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 4 (n=847)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 years - Month 6 (n=847)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EQ-5D by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EQ-5D by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 to 6 years - Month 2 (n=1154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 4 (n=1154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to 6 years - Month 6 (n=1154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 2 (n=1743)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 4 (n=1743)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 10 years - Month 6 (n=1743)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 2 (n=353)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 4 (n=353)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years - Month 6 (n=353)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EQ-5D by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
        <description>The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EQ-5D by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6</title>
          <description>The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-17 patients in prior month - Month 2 (n=1052)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 4 (n=1052)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-17 patients in prior month - Month 6 (n=1052)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 2 (n=1059)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 4 (n=1059)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-34 patients in prior month - Month 6 (n=1059)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 2 (n=1093)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 4 (n=1093)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=35 patients in prior month - Month 6 (n=1093)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EQ-5D by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
        <description>The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant indicates their health state by ticking the box against the most appropriate statement. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
        <time_frame>Baseline, Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>Participants received subcutaneous golimumab 50 mg once monthly for 6 months (study Month 1 to Month 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EQ-5D by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6</title>
          <description>The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant indicates their health state by ticking the box against the most appropriate statement. The digits (1 [best] to 3 [worst]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High disease activity - Month 2 (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 4 (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High disease activity - Month 6 (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 2 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 4 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity - Month 6 (n=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 2 (n=1926)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 4 (n=1926)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity - Month 6 (n=1926)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 2 (n=964)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 4 (n=964)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Month 6 (n=964)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Participant Acceptable Symptom State (PASS) at Month 4, Month 6, and Month 8</title>
        <description>The number of participants achieving PASS was evaluated at study Month 2, Month 4, and Month 6 was calculated. PASS is participant self-evaluation tool that uses a VAS 0mm (best) - 100mm (worst), with a score &lt;=31 representing an acceptable PASS.</description>
        <time_frame>Month 2, Month 4, Month 6</time_frame>
        <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR.</population>
        <group_list>
          <group group_id="O1">
            <title>GLM50-SC</title>
            <description>In Part 1 of the trial, participants received subcutaneous golimumab 50 mg once monthly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Participant Acceptable Symptom State (PASS) at Month 4, Month 6, and Month 8</title>
          <description>The number of participants achieving PASS was evaluated at study Month 2, Month 4, and Month 6 was calculated. PASS is participant self-evaluation tool that uses a VAS 0mm (best) - 100mm (worst), with a score &lt;=31 representing an acceptable PASS.</description>
          <population>The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Area Under the DAS28-ESR Curve From Study Month 6 to Month 12</title>
        <description>The DAS28-ESR is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR, and participant assessment of disease activity measure on a visual analogue scale. The DAS28-ESR has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). Minimum score=0 (best) to maximum score=10 (worst). The DAS28-ESR area under the curve can be calculated from the DAS28-ESR score versus time curve to provide an assessment of changes in disease activity over time.
The area under the DAS28-ESR score versus time curve was computed using the trapezoidal rule and using raw DAS28-ESR score values at Part-2 Baseline, end of Month 12, and at least 2 intermediate time points. The DAS28-ESR area under the curve was then averaged over the total duration (months) and expressed as units on a scale.</description>
        <time_frame>End of Month 6, End of Month 12</time_frame>
        <population>8 participants (3 poor quality data, 4 without a post-baseline DAS28-ESR, and 1 did not take Part 2 medication) and 7 participants (5 poor data quality, 1 without a DAS28-ESR at baseline, 1 without post-baseline DAS28-ESR) were excluded from the efficacy evaluable population for the IV-GLM 2mg/kg + SC GLM 50 mg and SC-GLM50 arms, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>IV-GLM 2 mg/kg + SC GLM 50 mg</title>
            <description>Participants received IV-GLM at a dose of 2 mg/kg at the start of Month 7, start of Month 8, and start of Month 10 if remission was not achieved at any of these IV administration visits. If remission was achieved, participants were switched to subcutaneous golimumab
at a dose of 50 mg once monthly.</description>
          </group>
          <group group_id="O2">
            <title>SC-GLM50</title>
            <description>Participants received SC GLM at a dose of 50 mg once monthly.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Area Under the DAS28-ESR Curve From Study Month 6 to Month 12</title>
          <description>The DAS28-ESR is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR, and participant assessment of disease activity measure on a visual analogue scale. The DAS28-ESR has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). Minimum score=0 (best) to maximum score=10 (worst). The DAS28-ESR area under the curve can be calculated from the DAS28-ESR score versus time curve to provide an assessment of changes in disease activity over time.
The area under the DAS28-ESR score versus time curve was computed using the trapezoidal rule and using raw DAS28-ESR score values at Part-2 Baseline, end of Month 12, and at least 2 intermediate time points. The DAS28-ESR area under the curve was then averaged over the total duration (months) and expressed as units on a scale.</description>
          <population>8 participants (3 poor quality data, 4 without a post-baseline DAS28-ESR, and 1 did not take Part 2 medication) and 7 participants (5 poor data quality, 1 without a DAS28-ESR at baseline, 1 without post-baseline DAS28-ESR) were excluded from the efficacy evaluable population for the IV-GLM 2mg/kg + SC GLM 50 mg and SC-GLM50 arms, respectively.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="0.992"/>
                    <measurement group_id="O2" value="3.67" spread="0.924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Remission</title>
        <description>Remission was defined as achievement of a DAS28-ESR &lt; 2.6.</description>
        <time_frame>Start of Month 8, Start of Month 9, Start of Month 10, Start of Month 11, End of Month 12</time_frame>
        <population>8 participants (3 poor quality data, 4 without a post-baseline DAS28-ESR, and 1 did not take Part 2 medication) and 7 participants (5 poor data quality, 1 without a DAS28-ESR at baseline, 1 without post-baseline DAS28-ESR) were excluded from the efficacy evaluable population for the IV-GLM 2mg/kg + SC GLM 50 mg and SC-GLM50 arms, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>IV-GLM 2 mg/kg + SC GLM 50 mg</title>
            <description>Participants received IV GLM at a dose of 2 mg/kg until remission is achieved at which time they were switched to SC GLM at a dose of 50 mg once monthly.</description>
          </group>
          <group group_id="O2">
            <title>SC-GLM50</title>
            <description>Participants received SC GLM at a dose of 50 mg once monthly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Remission</title>
          <description>Remission was defined as achievement of a DAS28-ESR &lt; 2.6.</description>
          <population>8 participants (3 poor quality data, 4 without a post-baseline DAS28-ESR, and 1 did not take Part 2 medication) and 7 participants (5 poor data quality, 1 without a DAS28-ESR at baseline, 1 without post-baseline DAS28-ESR) were excluded from the efficacy evaluable population for the IV-GLM 2mg/kg + SC GLM 50 mg and SC-GLM50 arms, respectively.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Month 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" lower_limit="15.3" upper_limit="25.4"/>
                    <measurement group_id="O2" value="13.7" lower_limit="10.0" upper_limit="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start of Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2" lower_limit="23.0" upper_limit="34.4"/>
                    <measurement group_id="O2" value="20.1" lower_limit="15.7" upper_limit="25."/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start of Month 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2" lower_limit="28.6" upper_limit="40.6"/>
                    <measurement group_id="O2" value="29.5" lower_limit="24." upper_limit="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start of Month 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3" lower_limit="34.3" upper_limit="46.8"/>
                    <measurement group_id="O2" value="39.3" lower_limit="33.5" upper_limit="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" lower_limit="38.2" upper_limit="50.9"/>
                    <measurement group_id="O2" value="45.1" lower_limit="39.1" upper_limit="51.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Golimumab 50 mg Subcutaneous (GLM50-SC)</title>
          <description>Participants received GLM50-SC once monthly for a period of 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Intravenous GLM (IV-GLM) 2 mg/kg + SC GLM 50 mg</title>
          <description>Participants received IV-GLM at a dose of 2 mg/kg at the start of Month 7, start of Month 8, and start of Month 10 if remission was not achieved at any of these IV administration visits. If remission was achieved, participants were switched subcutaneous golimumab
at a dose of 50 mg once monthly.</description>
        </group>
        <group group_id="E3">
          <title>SC-GLM50</title>
          <description>Participants received subcutaneous golimumab at a dose of 50 mg once monthly for a period of 6 months in Part 2 of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="203" subjects_at_risk="3357"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibriliation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Conductive deafness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Appendix disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastritis atrophic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lumbar hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oesophageal varicies hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Small intestine obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Calcinosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="3357"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Peritonsillar abcess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Abcess oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Beta haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Groin abcess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Herpes zoster oticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Listeria sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ludwig angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lymph node tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Syphillis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="3357"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Synovial rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lumbar spine stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Meniscal degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Polychondritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vulval cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nephrolithiases</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Renal amyloidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bronchopneumopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lung cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3357"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3357"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dermatitis psoriasiform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arterial bypass operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Arthrodesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lymphadenectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3357"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3357"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3357"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="245"/>
                <counts group_id="E3" events="19" subjects_affected="18" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3357"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="245"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator is granted the right to use the results of all work under this study including but not limited to, the results of tests and any raw data and statistical data generated for investigator's own teaching, research, and publication purposes only. Investigator/Institution agrees, on behalf of itself and its employees, officers, trustees, and agents, not to cause said results to be knowingly used for any commercial purpose whatsoever except as authorized by the sponsor in writing.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

